IgE in Non-Atopic Asthma by Chellappan Pillai, Prathap Lalithabai
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 








IgE in Non-Atopic Asthma
Chellappan Pillai, Prathap Lalithabai
Awarding institution:
King's College London
Download date: 05. Apr. 2019
1IgE in Non-Atopic Asthma
Prathap Pillai
A thesis submitted to King’s College London for the degree of
Doctor of Philosophy
2018
MRC & Asthma UK Centre in Allergic Mechanisms of Asthma
Department of Respiratory Science and Allergy
King’s College London School of Medicine
King’s College London
2I dedicate this thesis to my beloved wife, Preethy, for being on my side &
encouraging me throughout; and my supervisor Prof Corrigan for the
constant support and guidance. I wouldn’t have been able to
complete this work without their support.
3Abstract
Introduction
Previous studies suggest that IgE switching and synthesis occur in the bronchial mucosa of
“non-atopic” asthmatics, suggesting a role for IgE in asthma regardless of conventional atopic
status. To investigate this, I addressed the following hypotheses: (1) allergen-specific IgE is
manufactured in the bronchial mucosa of “non-atopic” asthmatics but does not appear in the
periphery; (2) naturally occurring IgE-specific IgG-autoantibodies may involve IgE in asthma
pathogenesis in an allergen-independent manner; (3) anti-IgE therapy improves lung function
and bronchial mucosal inflammation in non-atopic asthmatics in vivo.
Methods
(1) ImmunoCAP and ImmunoCAP ISAC microarrays were used to detect, quantify and
specify IgE in the bronchial mucosa of both atopic and non-atopic asthmatics; (2) bespoke
assays were developed to detect and quantify IgE-specific IgG autoantibodies in the sera of
atopic and non-atopic asthmatics, and positive sera examined for their ability to activate IgE-
sensitised human blood basophils in the presence and absence of allergen using a basophil
activation test, and to inhibit allergen binding to specific IgE on a rat basophilic cell line
stably expressing human FcεRI; (3) a randomised, double-blind, proof of concept study was 
performed to address the hypothesis that omalizumab therapy improves lung function and
reduces bronchial mucosal IgE expressing cells (utilising immunohistochemistry) in a group
of severe, non-atopic asthmatics.
Results
I found that (1) although the median total IgE concentration in bronchial mucosal
homogenates was significantly elevated in both non-atopic and the atopic asthmatics
4compared with controls, allergen component-specific IgE species were detectable only in the
atopic, and not the non-atopic asthmatics; (2) IgG autoantibodies binding to both free and
FcεRI-bound IgE were detectable in patients with atopic and non-atopic asthma as well as 
controls: some were able to activate IgE-sensitised basophils, whereas others inhibited
allergen-induced basophil activation, at least partly by inhibiting binding of IgE to specific
allergen; (3) omalizumab, but not placebo therapy of a group if non-atopic asthmatics for 20
weeks was associated with significant improvement in absolute and % predicted FEV1 despite
substantial reduction of existing anti-asthma treatment, along with a significant reduction in
the median total IgE+ cells (p<0.001) in the bronchial mucosa.
Conclusions
IgE is elevated in the bronchial mucosa of asthmatics termed ‘non-atopic’ by conventional
criteria. Although not allergen-specific, it may play a role in the pathogenesis of bronchial
mucosal inflammation in asthma, for example as a result of the effects of auto-anti-IgE
antibodies. Blockade of IgE binding to its receptors has the propensity to improve lung
function in non-atopic asthmatics.
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Chapter 1: General Introduction
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1. General Introduction
Asthma is a chronic disorder of the airways characterised by variable and recurring
symptoms, airflow obstruction, bronchial hyperresponsiveness and underlying inflammation1.
It is a leading cause of suffering, affecting about 300 million people worldwide. Asthma is the
most common chronic disease among children2. In the UK, over 5.2 million people are
affected which include 1.1 million children3. On average there is one hospital admission for
asthma every 7 minutes and one death every 7 hours. Although existing drugs control the
disease in most patients, in many thousands they do not, leaving them prey to severe daily
symptoms and unexpected exacerbations, which make their lives a misery. These patients
need new treatments urgently.
1.1 Asthma Classification
Asthma may be classified in many ways: clinically on the basis of various parameters
including the atopic status of the subject, the degree of airways obstruction or the nature of the
trigger precipitating an attack. The classification of asthma is complicated by the
multidimensional nature of the disease. Thus, the term asthma, like ‘arthritis’, equates to a
definition of grouped clinical and physiological characteristics4. Fig 1.1 is a schematic
representation of the term ‘asthma’.
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Fig 1.1: Schematic representation of the umbrella term ‘asthma’. The key clinical features of severity (lung
function, symptoms and exacerbations), inflammatory characteristics (particularly Th2 immunity) and their
division into associated phenotypes are shown. However, these phenotypes have not yet been fully
characterized4
1.1.1 The concept of Asthma Clusters and Clinical Asthma Phenotypes
The most recent approach to asthma classification is to define clusters, phenotypes and
endotypes of disease with a view to delineating the so-called “personalised management plan”
in the era of novel treatment strategies including biologics. Cluster analysis has been used in
an attempt to identify phenotypic subgroups of disease based on distinct patient and clinical
disease characteristics5. As this is classification system is still evolving and in its early stages,
several groups have proposed asthma cluster “phenotypes”. For example, the severe asthma
group from Leicester proposed 3 clusters emerging from their population data set of milder
asthmatics managed largely in primary care: i) early onset atopic, ii) obese non-eosinophilic,
iii) benign asthma; and 4 clusters of more severe patients typically managed in secondary
care: i) early onset atopic, ii) obese non-eosinophilic, iii) early symptom predominant and iv)
inflammation predominant (Fig 1.2). Interestingly, atopic status was not identified as a
27
significant discriminator influencing cluster membership in any of these clusters in either
primary or secondary care, although the prevalence of atopy significantly differed between the
clusters.
Figure 1.2: Summary of asthma phenotypes identified by cluster analysis in the primary and
secondary care by the Leicester severe asthma group5
The definition of a true phenotype (or endotype) requires a unifying and consistent natural
history, consistent clinical and physiological characteristics, an underlying pathobiology with








































































Table 1.1: One classification of asthma phenotypes based on similarity of clinical
characteristics4
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In essence, then, an asthma “phenotype” is characterised by common features such as clinical
characteristics (age, severity, BMI, airway reversibility), triggers (allergens, aspirin, obesity),
and some perception of the “degree” of inflammatory change in the airways. It might be
argued that phenotypic classification remains to an extent poorly discriminatory, vague and
arbitrary. It is scarcely surprising, therefore, that such classifications provide relatively little
basis for understanding pathophysiology of the disease, the significance of biomarkers and the
likely response to therapeutic strategies.
1.1.2 From phenotype to endotype
The concept of asthma “endotyping” is designed to move on from phenotyping towards the
identification of subgroups of asthma linked by distinct functional and/or pathophysiological
mechanisms6. Again, in view of the relative paucity of knowledge about the pathophysiology
of asthma, and the uncertain relationship between the pathogenesis of bronchial
hyperresponsiveness and airways obstruction and inflammation, endotyping of asthma is also
not without its difficulties at present. This is well illustrated when considering the role of
“atopy”, as conventionally defined, in asthma: little or nothing is known about the molecular
mechanisms which govern the continuous production of allergen-specific IgE in some
individuals but not others, or why this production results in clinical symptoms on exposure to
the relevant allergens in some individuals but not others. There is also a paucity of long term,
large scale studies characterising the natural history of such mechanisms over the lifetime of
an individual suffering from asthma or how these are linked with the presence of identified
phenotypic traits. The process will require consideration of clinical features, pathophysiology,
30
biomarkers, genetics, natural history and stability. One of the several proposed or tentative
asthma endotype classifications is presented in table 1.26.
Natural
history



























































































































Table 1.2: Evolving endotypes in relation to severe asthma
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There is strong evidence supporting a Th2-high phenotype in up to 50% of people with
asthma of any severity, yet 50% show no evidence for this immune process. Even the
percentage of early-onset allergic asthma that is truly Th2 high remains unknown.4
1.1.3 T cell immune responses in asthma
Prior to the 1980s it is fair to say that asthma was envisaged as a disease caused by periodic
contraction of hyperreactive airways caused by the release of histamine and other mediators
from IgE-sensitised mast cells on exposure to allergens. The “elephant in the room” with this
concept has always been that atopy, conventionally defined as the production of a systemic
IgE response to a series of arbitrary environmental proteins that we call “allergens”, is neither
necessary nor sufficient for the development of asthma. From the late 1980s onwards, data
emerging from many studies suggested that asthma is characterised by inflammation of the
airways mucosa, and more specifically by the elevated expression of Th2-type cytokines such
as IL-5, IL-4 and IL-13, thought then to originate from activated, Th2-type T cells. The
underlying assumption then was that these T cells are driven by immune responses to
allergens (Fig. 1.4) although formal proof of this assumption has never been produced,
probably because it is not in fact true. Very recently it has become clear that Th2-type
cytokines can be produced in large quantities by innate immune cells within the airways
mucosa such as ILC2s, and that these also strongly promote the local differentiation of Th2-
type T cells and local switching of B cells to IgE synthesis. In turn these ILCs are activated by
the alarmin cytokines IL-33, TSLP and IL-25, which are produced by bronchial epithelial
cells in response to a wide variety of environmental stimuli such as particulate pollution, viral
infections and inhaled proteins with intrinsic protease activity acting on protease-activated
receptors (PARs), including some allergens such as HDM7,8. Thus, the emphasis has shifted
away from asthmatic inflammation being driven primarily by allergen-driven responses:
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(Fig. 1.6). Indeed, it could be hypothesised that the IgE production observed in some
asthmatics is secondary to this alarmin-driven inflammatory process, and not the prime driver
of the disease. Patients with asthma may make IgE against all sorts of proteins presented
locally at the bronchial mucosa, which we normally do not classify and look for as
aeroallergens, e.g. the Staph enterotoxin IgE.
At the same time, it is certainly possible that alarmins/ILC2s/Th2 T cells do not drive the
airways inflammation observed in every asthmatic. For example, Th17 cells may induce
neutrophilic inflammation and other possible mechanisms driving non-Th2 asthma9-13 (Figs.
1.3 and 1.5).
Finally, airways inflammation is not the same as bronchial hyperresponsiveness (BHR),
which is an inherent abnormality of bronchial smooth muscle. Airways inflammation can
augment the clinical effects of BHR by reducing the internal diameter of the airways,
producing a greater degree of airways obstruction for a given degree of bronchial smooth
muscle contraction. Thus there will be some patients with BHR but little bronchial
inflammation: these patients correspond with the “early symptom predominant” sort of
patients (Fig 1.2): they have hypersensitive airways, but because they have little bronchial
inflammation they have occasional, benign symptoms. Most patients have BHR with a
moderate degree of airways inflammation, which responds to conventional anti-asthma
therapy (the “concordant” group in Fig 1.2).
Then there are patients with BHR who also have severe airways narrowing driven by alarmins
and possibly secondary remodelling of the airways, resistant to steroid reversal. With these
patients, any acute exacerbation of airways narrowing by increased inflammation or mucin
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production, such as by a viral URTI, is likely to result in critical airways narrowing, with
repeated visits to hospital with severe asthma episodes. Anti-IL-5 biologicals reduce this
inflammation somewhat by reversing some of the eosinophilic infiltration and thus increasing
the internal airways diameter and thereby reducing the frequency of asthma exacerbations in
treated patients. Anti-TSLP14 (and anti-IL-33, if it ever appears), should theoretically be better
than anti-IL-5 for this, resulting in a reduced incidence of exacerbations15.
Until recently, there was no known functional linkage between BHR and airways
inflammation in asthma, other than the fact that inflammation, by narrowing the lumen of the
airways, greatly exacerbates the blockage arising from a given degree of bronchial smooth
muscle contraction. Recent work on the calcium sensing receptor published recently in
Science16 reveals that this protein regulates bronchial smooth muscle intercellular calcium
concentrations, causing the muscle contract more intensely in response to any contractile
stimulus, which could be the main mechanism driving BHR. Further, other cationic proteins
may act as agonists at this receptor, most notably eosinophilic cationic proteins and
polyamines such as spermine and spermidine from neutrophils7. These observations provide
the basis for the first ever-functional link between inflammatory cellular infiltration and direct
exacerbation of BHR.
1.1.3.1 Th2 versus non-Th2 asthma
Almost since the inception of the concept that immunity can be divided into Th1 and Th2 type
processes, asthma has been considered a Th2 process4. Although asthma has classically been
considered a disease of Th2 immunity, the complex clinical heterogeneity of the disease is
increasingly recognised. Th2 cells and the cytokines that they secrete are distinct features of
the allergic response in atopic asthmatic patients; however, other effector T-cell populations
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are also observed in the lung. Thus the molecular mechanisms that drive the underlying
pathology in the allergic lung are likely to involve a more diverse panel of cytokines than the
classical Th2 family. This might indicate contribution from different immune pathways in
eliciting disease. Asthma is a heterogeneous disease that is driven by numerous T-cell subsets,
Th2 and non-Th2, (e. g. Th17, Th9) and the interactions between genetic susceptibility and
the environment determine the pathophysiology of disease17.
1.1.3.2 Th2 associated asthma
As elucidated above, asthma has traditionally been considered a Th2 process that is linked
strongly to atopy and allergy, type I hypersensitivity reactions, eosinophilic inflammation and
response to corticosteroids. The data from many studies suggest that the majority of - but,
clearly, not all -asthma cases fit this traditional view5,18. Current phenotyping approaches
support the existence of an early-onset, mostly atopic and allergic asthma phenotype, and
most have additionally identified a later-onset (often age 20 or later) eosinophilic phenotype.
The molecular and targeted therapy data support an overall Th2 association with both of these
phenotypes, such that these two clinically different yet immunologically overlapping
phenotypes may fall into a broader category of Th2-associated asthma. Finally, the clinical
phenotype of exercise-induced asthma (EIA) is also likely to have a Th2 component, given its
eosinophil and mast cell related profile19,20.
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Figure 1.3: Theoretical grouping of emerging asthma phenotypes based on the distinction between
Th2-high asthma and non-Th2 asthma. Th2 asthma consists of both early- and later-onset disease over
a range of severities. It is likely that the majority of early-onset allergic asthma is mild but that an
increasing complexity of immune processes leads to greater severity. Later-onset eosinophilic asthma
without traditional allergic elements is more likely to be severe, whereas EIA is a milder form of Th2
asthma. Non-Th2 asthma includes very late–onset, obesity-associated asthma as well as smoking-
related and neutrophilic asthma, and asthma in which affected individuals show little inflammation.
The intensity of the colours represents the range of severity; the relative sizes of the sub-circles
suggest relative proportions of affected individuals4.
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Figure 1.4: Th2 immune processes in the airways of people with asthma. The pathway begins with the
development of Th2 cells and their production of the cytokines IL-4, IL-5 and IL-13. These cytokines
stimulate allergic and eosinophilic inflammation as well as epithelial and smooth muscle changes that
contribute to asthma pathobiology. APC, antigen-presenting cell; CRTH2, chemo-attractant receptor-
homologous molecule expressed onTh2 cells; iNOS, induced nitric oxide synthase; PGD2,
prostaglandin D2; TSLP, thymic stromal lymphopoietin.
1.1.3.3 Non-Th2 asthma4
Non-Th2 asthma is likely to represent a substantial proportion of all asthma. Compared with
Th2 asthma, however, relatively little is understood about this asthma subgroup, the
phenotypes underlying it or the molecular elements that control it. Non-Th2 asthma may
affect 50% or more of corticosteroid-naïve individuals, who, although they meet the criteria
for asthma, show less airway obstruction and hyperreactivity than people with Th2 high
asthma. Many people who have mild to moderate adult-onset asthma and no history of
childhood allergic features are likely to fall into this category. As these individuals also
respond poorly to corticosteroid therapy, in the absence of validated Th2 biomarkers, the
proportion of non-Th2 asthma in persistently symptomatic, corticosteroid-treated patients is
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not clear. However, the lack of efficacy of Th2 targeted therapies in studies of non-
phenotyped, corticosteroid-treated patients (even when corticosteroid treatments are tapered)
and the existence of multiple other pathways by which airway hyperresponsiveness may
develop strongly suggest that a subset of asthma exists with no Th2 immunity.
The major Th2 and non-Th2 asthma phenotypes and their features are listed in table 1.1. Their
grouping based on clinical characteristics is illustrated in figure 1.3. The molecular and
immune processes are schematically illustrated in figures 1.4 and 1.5.
Figure 1.5: Theoretical range of factors that may be involved in the development of non-Th2 asthma.
These factors include infection-related elements, Th1 and Th 17 immunity, non-Th2 associated
smooth muscle changes, including genetics and oxidative stress, and the development of neutrophilic
inflammation. IFN-γ: interferon-γ; GRO-α: growth-regulated oncogene-α; PAMP: pathogen-
associated molecular pathway; DAMP: danger-associated molecular pathway; TLR: Toll-like receptor.
1.2 Atopic and Non-Atopic Asthma: “The Concept”
By convention, the classification of asthmatic patients as atopic or non-atopic is based on
whether or not their symptoms may be precipitated or aggravated upon contact with one or
more local environmental, airborne proteins recognised a being capable of inducing a specific
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IgE response and acute release of histamine from mast cells and basophils sensitised by this
specific IgE (“aeroallergens”), supported by the demonstration of these allergen-specific IgE
antibodies as evidenced by positive skin prick and/or serological tests. Rackemann first
introduced the terms “extrinsic” and “intrinsic” asthma in 194721. He observed in a study of a
limited number of patients a form of the disease in which extrinsic factors were triggering the
symptoms and another in which no specific triggering factor could be identified. He called the
former “extrinsic asthma” and the latter “intrinsic asthma”. According to Rackemann,
“extrinsic” asthma was easier to diagnose, associated with vasomotor rhinitis, allergy and of
onset before the age of 30. “Intrinsic” asthma was more difficult to diagnose and associated
with polypoid sinusitis. More recently, and not necessarily in line with Rackemann’s view of
external “triggers”, the differentiation between the two entities has been focussed on the
presence or absence of positive skin prick and/or serological tests to common aeroallergens
rather than purely on the basis of a clinical history of symptoms on allergen exposure.
Nowadays, these terms have become equated with the presence or absence of co-existing
atopy, defined as the propensity of some individuals to mount specific IgE responses to
certain antigens (“allergens”) encountered at mucosal surfaces as detected by skin prick or in
vitro tests. Although in allergic (“extrinsic”) asthmatics exposure to allergens may cause
asthma exacerbation, other environmental influences (such as viral infections) more
commonly exacerbate asthma regardless of atopic status. A series of studies designed to
analyse the immunopathological differences between atopic and non-atopic asthma resulted in
the conclusion that both kinds of asthma share more similarities than differences22,23. Nieves
et al. conducted a relatively large population study in 751 asthmatics to understand the
discriminating characteristics between the two groups and concluded that despite the
immunopathological similarities, atopic and non-atopic asthma reflect distinct clinical
groups24. Age, age of onset of asthma, and female/male ratio were higher in non-atopic than
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in atopic asthmatics. Conversely, atopic asthma typically commenced at an earlier age with a
higher male/female ratio and was more associated with rhinitis and smoking. In the above
survey, about a quarter of patients were non-atopic, whereas an earlier Swiss SAPALDIA
survey concluded that a third of total asthmatics were non-allergic (intrinsic)25,26. An even
higher prevalence of non-atopic asthma has been reported by some later studies: for example,
the prevalence of non-atopic, severe asthma was estimated at 50% of the total in the
ENFUMOSA cross sectional study27 and 17–34% in the SARP study18. Early epidemiological
studies suggested that non-atopic asthmatics form an identifiable clinical group (more likely
female, late onset, severe disease)28. These clinical distinctions between atopic and non-atopic
asthma led to speculation about their causation being fundamentally different, in particular
regarding the involvement of IgE-mediated responses29.
Ever since the first description of intrinsic asthma, because of the all-pervading concept that
asthma must be driven by “allergic inflammation” in the airways, there has been debate about
its pathogenesis26. The fact that many asthma exacerbations, and consequently many first
presentations of asthma are brought about by upper respiratory viral infections led to the
suggestion that non-atopic asthma may represent a form of autoimmunity triggered by a viral
infection such as influenza. Certainly, non-atopic asthmatics frequently demonstrate positive
autologous serum skin tests, evidence of circulating histamine releasing factors and positive
anti-nuclear auto-antibodies30. It has also been postulated that “non-atopic” asthmatics
manufacture IgE against as yet undetected or unidentified “allergens” and may therefore
benefit from allergen avoidance31,32 (Figure 1.6). For example, the airways epithelium of
asthmatics may sometimes be colonised by microbes such as Staphylococcus, which produce
superantigens. Superantigens produced locally in the airways may lead to class switching of
local B-cells, resulting in polyclonal IgE production in the airways and also the production of
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specific IgE against the these superantigens33,34. This may also promote production of IgE
against other “allergens”. Superantigens can also stimulate clonal expansion of T-cells,
resulting in clonal activation of Th2 cells and CD8+ cells and suppression of regulatory T
cells35,36.
While exposure of some asthmatic patients to some aeroallergens to which they are clinically
sensitised may be a significant acute exacerbating factor for their symptoms (for example,
seasonal or “pollen” asthma), the actual role of IgE-mediated reactions in asthma
pathogenesis per se remains obscure. Arguably, we are moving away from thinking of asthma
as being “caused” by “allergic inflammation” dependent on the presence of IgE directed
against an arbitrary range of aeroallergens. It is becoming more and more clear that what we
are accustomed to call “allergic inflammation” is unlikely driven by allergen-specific
responses at all, and indeed that at least some IgE production may arise as a consequence of
alarmin-driven Th2-type inflammation with B cell switching to IgE within the bronchial
mucosa. It is hardly surprising, therefore, that the profiles of inflammatory cellular infiltration
of the airways in “extrinsic” and “intrinsic” asthma are essentially the same (see next section).
Extrapolating from the hypothesis that switching of local B cells to IgE producing plasma
cells is a consequence, rather than a cause of the airways inflammation in asthma, it is
conceivable that at least some of the resulting local mucosal IgE production is not directed at
what are conventionally called “aeroallergens”, but other proteins which have access to the
airways through inhalation or because, for example, they are produced by commensal
microorganisms such as Staphylococcus referred to above. In conclusion, the distinction
between “allergic” and “non-allergic” inflammation may not be as distinct as Figure 1.7
suggests, and potentially all of these mechanisms are part of epithelial alarmin-driven
inflammation of the airways. Certainly, previous studies on this topic have revealed
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remarkable similarities in the cellular and molecular immunopathology of atopic and non-
atopic asthma and the possibility of a role for IgE antibody in both clinical phenotypes of
disease rather than confirming distinct pathogenetic mechanisms22,23,37-40.
1.3 Atopic and non-atopic asthma, similarities and differences:
The pathogenic mechanisms of non-atopic asthma in comparison to its atopic counterpart
have always been a subject of debate. Although clinically are two distinct entities, more
similarities than differences have been observed between the two in terms of
immunopathogenesis, underlying IgE mechanisms, and so on. More information has become
available in recent years comparing the ultrastructure of the epithelium in these two types of
asthma. A comparison of airway epithelium/immunopathology in atopic and non-atopic
asthma is presented in the figures (Figures 1.6 & 1.7) and tables (Tables 1.3, 1.4 & 1.5) in the
following pages, from the available information in the literature22,37-53. Similarities outnumber
the differences, until we unravel the mystery surrounding these two important phenotypes of
asthma in more detail.
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Figure 1.6: One theoretical, postulated mechanism of non-atopic asthma. In the absence of atopy, unknown
antigens could presumably trigger local IgE production. Such antigens, as in atopic asthma, lead to the release of
pharmacological inflammatory mediators that cause rapid onset bronchospasm and chronic asthma54
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Fig 1.7: Two different pathways leading to airway inflammation in asthma55. In allergic asthma, dendritic cells
present allergens to CD4+ T-cells, inducing T-helper (Th2) cells, which produce interleukin IL-4, IL-5 and IL-
13, and leading to IgE switching in B-cells, airway eosinophilia and mucous hypersecretion. In non-allergic
eosinophilic asthma, air pollutants, microbes and glycolipids induce the release of epithelium-derived cytokines,
including IL-33, IL-25 and thymic stromal lymphopoietin (TSLP), which activate innate lymphoid cells (ILCs)
in an antigen-independent manner via their respective receptors: IL-17 receptor B (IL-17RB), ST2 and TSLP
receptor (TSLPR). Activated ILC2s produce high amounts of IL-5 and IL-13, leading to eosinophilia, mucus
hypersecretion and airway hyperreactivity. CRTH2: chemo-attractant receptor homologous molecule expressed
on Th2 cells; ALX/FPR2: receptor for lipoxin A4; FcεRI: high-affinity receptor for IgE; GATA3: GATA-
binding protein 3; PG: prostaglandin; ROR: retinoic acid receptor-related orphan receptor; NK: natural killer;
MHC: major histocompatibility complex; TCR: T-cell receptor.
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Cell types or epithelial
components
Atopic asthma Non-atopic asthma
Ciliated columnar Damage +++ Damage +
Desmosomes Breakdown ++ Breakdown +
Goblet cells Hyperplasia+ Hyperplasia -
Basal cells Damage +/- Damage +/-
Basement membrane Thickening++ Thickening+
Eosinophils Infiltration+++ Infiltration+++
Neutrophils Infiltration+ Infiltration++
Mast cells Infiltration++ Infiltration+
Lymphocytes Infiltration+++ Infiltration++
Macrophages Infiltration+ Infiltration++
Table 1.3: Comparison of bronchial epithelial components in atopic and non-atopic
asthma56
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Cytokines and receptors Atopic asthma Non-atopic asthma
Th1
γ IFN (sputum) ++ ++
IL-2 (BAL fluid) + ++
IL-2R+ + +
Th2
IL-4 ++ +/- ++
IL-4α Receptor ++ ++
IL-5 ++ +/- ++
IL-5α Receptor ++ ++
IL-10 (Sputum) ++ +
IL-13 ++ ++
GMCSF ++ ++
Th1&Th2 IL3 ++ ++
Macrophage GMCSFR-α + +++
Table 1.4: Cytokine and cytokine receptor expression in the respiratory epithelium and
sub mucosa56
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IgE related expression Atopic asthma Non-atopic asthma
CD20+ B cells ++ ++






Table 1.5: IgE and related molecules in the respiratory mucosa56
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1.4 IgE and its role in allergy
IgE, the fifth and least abundant class of immunoglobulins, is thought to have evolved in
mammals as a first line defence mechanism against parasites, particularly helminths and
protozoa. Today it is perhaps better known as a mediator of type 1 hypersensitivity or allergic
reactions ranging from allergic rhinitis and asthma to life-threatening anaphylaxis. IgE is the
antibody potentially capable of evincing clinical sensitivity to allergens. It shares the same
basic molecular architecture as antibodies of other classes, with two identical heavy chains
and two identical light chains (Fig: 1.8). IgE has 4 heavy chain domains (Cε1-Cε4) and differs 
from other antibody isotypes by being located predominantly in tissues, bound to mast cells
and basophils through its high-affinity receptors. In this cell-bound state IgE can persist for
extended periods of time. Most of the IgE is retained in tissues, and free serum IgE
concentrations are the lowest of all immunoglobulin classes. IgE does not activate
complement and exerts functions principally through its receptors. The high-affinity receptor
“FcεRI” is expressed on basophils and mast cells as a αβγ2 tetramer and on Langerhans cells, 
myeloid dendritic cells (DCs), plasmacytoid DCs, monocytes and eosinophils as a αγ2 trimer.
The low-affinity receptor FcεRII (CD23) is a C-type lectin and of two types- CD23a and 
CD23b. CD23a can be identified on activated B cells, and CD23b on a wide variety of cells
such as B cells, macrophages, eosinophils, natural killer cells, T cells, follicular dendritic
cells, airway epithelial cells and smooth muscle cells 57.
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Fig: 1.8 Basic molecular structure of IgE (in comparison with IgG)58
The discovery and characterization of the antibody class now called IgE59 , culminating in the
independent descriptions of this class of antibodies by the Ishizakas60 and Johansson and
Bennich61, arguably represents the most crucial advance in our understanding of the
immunological basis of allergic disorders. Production of antigen-specific IgE requires that
such antigens are taken up by dendritic cells, B cells or other antigen-presenting cells which,
in the presence of interleukin-4 (IL-4) or IL-13 provided early in the process by one or more
cell types, present the processed antigens to cognate naive T cells that then acquire a
T helper type 2 (Th 2) cell phenotype62. Th 2 cells both engage cognate B cells through B cell
major histocompatibility complex (MHC) class II and co-stimulatory molecules and secrete
IL-4 and IL-13, inducing B cells to undergo class-switch recombination (CSR), resulting in
the variable, diverse, and joining (VDJ) segments initially linked to another constant (C)
region in the immunoglobulin heavy chain locus (for example, Cμ or Cγ) to instead being 
linked to the Cε region. CSR may also be induced by IL-4 and/or IL-13 derived from cells 
other than Th 2 cells, which may include mast cells and basophils62-64.
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Antigen sensitization was previously thought to occur primarily in lymphoid germinal
centres, but IgE-producing B cells that undergo clonal selection and affinity maturation may
also be generated in the mucosal associated lymphoid tissue including that of the respiratory
mucosa65 . CSR resulting in production of IgE (in addition to IgA) also can occur in the
gastrointestinal tract, and patients with food allergy have higher concentrations of IgE in the
gastrointestinal tract than healthy individuals66. Such evidence supports the conclusion that
IgE can be produced locally by B cells in the gut- or airway-associated lymphoid tissue, as
well as in the lymph nodes, of individuals with food allergy, seasonal or perennial allergic
rhinitis67 or atopic or non-atopic asthma.
These observations suggest that much of the IgE responsible for ‘organ-specific’ allergic
disorders may be produced locally in the affected anatomical sites, which also may be a
survival niche for long-lived IgE-antibody–secreting plasma cells, and that IgE measured in
the peripheral circulation may be primarily antibody that has escaped from the site of disease.
Indeed, concentrations of IgE in the peripheral blood are typically much lower than those of
any other immunoglobulin isotype58. These findings also suggest that locally produced IgE
may be pathogenic in at least some cases of so-called non-atopic asthma under circumstances
in which it may be difficult to detect crucial IgE antibodies systemically, particularly in
individuals in which no triggering antigen has been identified. 65
The sites of IgE production in human subjects and the nature and characteristics of IgE-
producing cells are of great interest. In this context, it has been shown that allergen-specific
IgE levels can be boosted by contact with allergens via the respiratory mucosa of the nose.
Also, it has been proposed that allergy effector organs (e.g., the nasal mucosa and the lung)
may be important sites of IgE production in allergic patients. IgE-producing cells have also
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been found in the blood, but their numbers are extremely low. Transfer of specific
sensitization during bone marrow transplantation indicates the presence of IgE-producing B
memory cells or plasma cells also in the bone marrow.
The half-life of free serum IgE is rather short in comparison to other immunoglobulin classes
-12 h in mice68 and 2–3 days in humans69,70. Although the survival of IgE antibody can be
markedly increased by binding to its high affinity receptor, FcεRI, or its low affinity receptor, 
CD2371, it has to be produced continuously in order for serum concentrations to be
maintained. The investigation of IgE production and metabolism in humans is hampered by
the small numbers of IgE-producing cells in blood, nasal mucosa or tonsils. Therefore, our
knowledge of the location and precise mechanisms of IgE production and of the metabolism
of IgE-producing cells is mostly based on extrapolation of data obtained in mouse models and
in vitro systems using peripheral blood mononuclear cells (PBMCs) or tonsil-derived B cells.
Based on our current knowledge, the potential locations of IgE production are blood, nasal
mucosa, lungs, adenoid, tonsils, spleen and bone marrow. After leaving the bone marrow,
mature IgM- and IgD bearing B cells with specificity for allergens become activated upon
recognition of their cognate antigen. Subsequently, they interact with T cells, which have
previously been activated by allergen presentation through professional antigen-presenting
cells. The cytokines interleukin (IL)-4 and IL-13 produced by activated T helper 2 (Th2) cells
promote the class switch to IgE62. Whether the switch to IgE occurs directly or via other
switch stations is a matter of debate. In humans, switching to IgE can occur apparently either
directly or via IgG of all four classes72-74. Switching via Sγ was demonstrated in a human cell 
line75 as well as in nasal mucosal samples from allergic patients74. In a group of children from
a birth cohort who acquired allergy during their first 7 years of life, indices of both direct and
sequential class switching were observed76.
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Whether IgE memory in human allergic patients is due to the existence IgE memory cells or is
sustained by long-lived IgE plasma cells and a pool of IgG memory B cells with specificity
for allergens that switch to IgE production upon allergen contact is currently under debate57,77-
81. So far, only a few sites in the human body have been thoroughly investigated directly for
the presence of cells involved in allergen-specific IgE memory. Although IgE antibodies and
their role in allergic disease were first described in 196782, the source that continuously
replenishes serum IgE levels is still far from clear. It appears unlikely that a small number of
cells present in the peripheral blood could constantly produce as much allergen-specific IgE
as is needed to arm mast cells and basophils for their effector function. In this context, it is
likely that approximately 0.2 % of the serum IgE is newly produced by blood-derived plasma
cells83. The current observations indicate that there are few IgE-producing cells in the blood,
but that the majority of IgE-producing cells in human allergic patients reside elsewhere. In
previously sensitized allergic patients, respiratory contact with relevant allergens is followed
by a substantial systemic elevation of specific IgE antibodies84-87. It has been proposed that
this allergen-contact induced elevation of IgE antibody production may arise locally in the
airways mucosa. The presence of allergen-specific IgE in nasal secretions of allergic patients
was recognised as early as 197988. Recent clinical studies have revealed that a substantial
number of patients with rhinitis without detectable, serum allergen-specific IgE and with
negative skin prick tests mounted a positive response to specific allergens in nasal
provocation tests and also had specific IgE antibodies in nasal secretions89,90. Nasal mucosal
biopsies from symptomatic allergic rhinitis patients but not from non-allergic controls
contained increased numbers of IgE-positive B cells and plasma cells and allergen-specific
plasma cells67. To investigate whether these IgE-producing cells derived from more distant
lymphatic tissue or whether they were resident to the nasal mucosa and performed class
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switch to IgE locally, biopsies of nasal mucosa from allergic patients were challenged ex vivo
with allergen73,74,91-93. Interestingly, not only local synthesis of ε germline transcripts92,93, but
also ε circle transcripts as signs of mature IgE synthesis73,74 could be detected in the biopsies
upon allergen challenge. Upon inhalation of airborne allergens, not only the nasal mucosa but
also other lymphatic tissue of the airways, such as the adenoids and the tonsils as part of the
Waldeyer’s lymphatic ring, are potential sites of allergen encounter. In this context, tissue
homogenates of adenoids of atopic children showed higher levels of total and allergen-
specific IgE compared to non-atopic children94. Using immunohistochemical staining, IgE+
cells were identified mainly in the extrafollicular area of the adenoids of atopic subjects,
whereas adenoids of healthy controls contained only very few IgE + cells95. Those IgE + cells
were identified mainly as plasma cells and macrophages using double staining for IgE and the
plasma cell marker CD138 or the macrophage marker CD68, respectively96. Furthermore,
tonsil-derived PBMCs also produced IgE when cultured in vitro and stimulated with
pokeweed mitogen97,98. The presence of allergen-specific IgE in the sputum of house dust
mite-sensitised asthmatic patients indicates that local IgE production may also occur in the
airways of patients suffering from allergic asthma99. Analysis of IgE transcripts of a bronchial
biopsy of a polysensitised asthmatic patient indicated that IgE-synthesising B cells may also
be found in the airways of humans100. However, class switch recombination to IgE has been
observed in bronchial biopsies of both atopic and non-atopic asthmatic patients but not in
atopic control subjects not suffering from asthma53,101. Thus, local IgE synthesis in the lung
seems to be one characteristic of asthma regardless of the conventional atopic status of the
patient potentially due to the fact that the high alarmin/high Th2 environment typical of
asthmatic inflammation may be conducive to B cell switching to IgE in all asthmatics,
regardless of their conventional atopic status. IgE-producing cells were detected in the spleen
of aerosol-challenged mice that had previously sensitised to ovalbumin102. Whether this also
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applies for human allergic patients is so far not clear, as data on the presence of IgE producing
cells in human spleen are rare. One report analysing the spleen of an atopic patient sensitised
to house dust mite who died from an asthma attack, showed that IgE was also produced in the
spleen103. However, the nature of the IgE-producing cells and the specificity of the IgE
antibodies produced were not reported.
Some case reports and small studies investigated the effect of transferring bone marrow from
an atopic donor into a non-atopic recipient104-109. The results are ambiguous. In some case
reports, non-atopic recipients receiving bone marrow from atopic donors developed
sensitisation profiles similar to those of their donors104-107. However, it has also been shown
that not all recipients acquire the allergic profile of their donors108 and that some of the
patients also acquire de novo allergic sensitisations in addition to those transferred from the
donor109. Thus, IgE memory seems to be transferable; however, to which extent and which
cells – long-lived plasma cells or memory B cells – are responsible remain to be addressed.
1.5 The concept of allergen sensitisation, IgE production and facilitated antigen
presentation110 (Figure 1.9)
Initial allergen sensitisation results in antigen-specific IgE production (left half of the figure
1.9). In individuals not yet exposed to a new environmental allergen, the only IgE present
(blue in the figure 1.9) does not have specificity for the new antigen(s). Such IgE can be
bound to the αβγγ form of FcεRI on mast cells or to the αγγ form of FcεRI on the surface of 
macrophages, monocytes or dendritic cells or to CD23 on airway epithelial cells or other
cells. The new antigens (orange circles in the figure 1.9) are captured by dendritic cells or
macrophages in the airway lumen or in the epithelium of the airway mucosa or gain access to
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sub-mucosal dendritic cells through disrupted epithelium or, for some antigens with intrinsic
protease activity, by disrupting epithelial cell tight junctions. Antigen-activated dendritic cells
mature and migrate to regional lymph nodes or to sites in the local mucosa, where they
present processed antigen epitopes to cognate T cells; in the presence of IL-4 or IL-13, which
may be derived from a variety of potential cellular sources, this induces such T cells to
become differentiated and activated Th 2 cells. The key molecular switch for Th2
development is interaction of the T cell accessory molecule OX40 with its ligand OX40L
expressed by dendritic cells primed by TSLP111. Thus again, it is likely this epithelial alarmin,
which creates the environment in the respiratory mucosa for Th2 T cell differentiation. The
OX40/OX40 ligand interaction activates NFAT (Nuclear Factor of Activated T-cells) which
in turn triggers IL-4 production by the T cell, which by acting on its own IL-4 receptors in
turn activates the key molecular T cell switches for Th2 development: STAT6 and GATA-
3112. The Th2 cytokines IL-4 and IL-13 also activate immunoglobulin heavy chain gene CSR
for antigen-specific IgE production, designated antigen-specific IgE, in B cells. The antigen-
specific IgE response is amplified by FAP and other mechanisms (right half on the figure 1.9).
Antigen-specific IgE can bind to multiple cell types through IgE receptors. Antigen-induced
aggregation of IgE bound to FcεRI stimulates mast cell degranulation and the release of 
mediators such as histamine, PGD2 and TNF, which promote recruitment of Th2 cells, the
migration, maturation and activation of dendritic cells and antigen presentation. IgE and
antigen-IgE complexes can cross the epithelium by transcytosis mediated by CD23 on airway
epithelial cells (① on Fig 1.9), allowing them to bind to and activate FcεRI on mast cells and 
dendritic cells. This process contributes to the perpetuation of allergic inflammation and,
potentially, through promotion of IL-4 and/or IL-13 secretion by mast cells (② on Fig 1.9)
and effects of activated mast cells on dendritic cells (③ on Fig 1.9), to additional local IgE
CSR and IgE production in B cells, either to additional epitopes of the original antigen or to
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new antigens bound by dendritic cells (square blue symbols in figure 9). As discussed
previously, we do not yet understand whether the inflammation seen in the airways of
asthmatics is truly “allergic inflammation” or alarmin-driven inflammation with the
production of IgE playing a minor role or possibly epiphenomenal. Antigen presentation
mediated by binding of antigen-IgE complexes to CD23 on B cells, followed by antigen
presentation by these B cells to cognate T cells, is called Facilitated Antigen Presentation
(FAP) (④ on Fig 1.9), a process that can result in epitope spreading, with production of IgE
recognising new epitopes of the original antigen or to epitopes of new antigens, and the
subsequent precipitation of allergic symptoms. FcεRI αγγ trimers on other antigen-presenting 
cells (e.g. dendritic cells, monocytes and macrophages) permit these cells to bind and
internalise IgE bound to complex antigens; epitopes derived from such antigens, including
those comprising epitopes for which there is not yet a specific IgE response, are then
presented to cognate T cells, which, in the presence of IL-4 and/or IL-13, can become Th 2
cells that in turn promote the production of IgE against these new epitopes by B cells (⑤ on
Figure 1.9).
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Initial sensitisation leading to antigen
specific IgE production
Amplification of antigen-specific IgE
response by FAP and other mechanisms
Figure1.9110: Allergen sensitisation and IgE production
(Ag: environmental allergen/antigen, ICOS: Inducible T Cell Co-Stimulator, ICOSL: ICOS
ligand, BCR: B Cell Receptor)
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1.6 IgE in atopic asthma
Allergic asthma and allergic rhinitis/conjunctivitis are characterised by a Th2-dominated
immune response associated with detectable circulating IgE specific for inhaled aeroallergens.
Symptoms of atopic asthma are intermittent attacks of breathlessness, wheezing and cough
after exposure to inhaled allergens or other potential triggers such as viral infection. These
appear to be caused by chronic inflammation and remodelling of the conducting airways on a
background of bronchial hyperresponsiveness. Atopic rhinitis or conjunctivitis is an
inflammation of the nasal passages or conjunctiva, usually associated with swelling, watery
nasal discharge, and itching of the nose and eyes. The association between allergen specific
serum IgE levels and asthma was established through epidemiologic studies. Burrows et al
found a close correlation between serum total IgE concentrations, skin test reactivity and
asthma. Antigens involved are mostly indoor aeroallergens derived from, for example, house
dust mite, animal dander, cockroach, and moulds113. But more clarity is needed here to
distinguish cause and effect: does IgE “cause” asthma or is elevated IgE production a
bystander product of alarmin-driven mucosal inflammation in asthma, or both? This question
is further complicated by the fact that the amount of allergen-specific IgE detectable by
SPT/in vitro testing bears no relationship to the severity of the reaction, if any, to allergen
exposure. Might allergen-specific IgE play a role in asthma even if it does not cause any
immediate clinical symptoms? It is not clear whether IgE is capable of causing or
exacerbating asthma without causing acute symptoms, possibly by activation of effector cells
such as eosinophils or facilitated antigen capture and presentation by B-cells or APCs.
Furthermore, asthma correlates best in epidemiological studies with total circulating IgE, not
allergen specific IgE. Does this mean that IgE causes asthma regardless of its specificity, or is
it that individuals who are more prone to develop alarmin-induced inflammation of their
airways are more likely to manufacture IgE? Are there common genetic and/or environmental
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influences which lead to both asthma and excessive IgE in the system, either due to increased
production and/or reduced breakdown or removal from the circulation?
1.7 IgE in “non-atopic” asthma
Asthmatic patients who do not respond to common aeroallergens on skin prick testing or have
negative serological tests to the same are described as non-atopic. About a third of adult
asthmatic patients are non-atopic by this definition. Non-atopic asthmatic patients usually
have more severe and difficult-to-control disease28. They also have increased total serum IgE
concentrations compared with those seen in healthy control subjects, although experimental
“asthma” can be induced in animals in the absence of B cells or IgE, an observation
compatible with the hypothesis that IgE is not indispensible for the development of asthma114-
117.
Previous studies comparing the cellular and molecular immunopathology of atopic and non-
atopic asthma have revealed remarkable similarities, consistent with the hypothesis that, if
IgE does play some role in the pathogenesis of asthmatic airways inflammation, this is
regardless of the presence or absence of conventional “atopy”. Thus:
(i) The bronchial mucosal inflammatory cellular infiltrate is mostly identical except for an
excess of tissue macrophages in non-atopic patients118. Furthermore, there is equivalent,
elevated expression of the cytokines IL-4 and IL-13, which are the only human
cytokines capable of isotype switching B cells so that they make IgE antibodies22,119,120.
There is also equivalent, elevated expression of a wide range of cytokines, chemokines
and their receptors implicated in asthma pathogenesis121-124.
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(ii) It has long been known from epidemiological studies that high total serum IgE
concentration is a risk factor for airways obstruction113. A more recent study showed
that in a large unselected cohort of non-atopic patients defined by negative skin prick
tests, asthma was fivefold more prevalent and airways obstruction more severe in those
subjects with serum IgE concentrations in excess of the “normal” upper limit of 150
IU/ml125. These studies make no reference to the specificity of the IgE, and indeed
suggest that inappropriate IgE production is a risk factor for asthma independently of
specific IgE responses to allergens.
(iii) More compelling evidence for local IgE synthesis has come from the demonstration of
elevated expression of IgE  heavy-chain germ line and mature gene transcripts in the
bronchial mucosa of non-atopic as well as atopic asthmatics compared with controls in
the absence of elevated numbers of B cells126. This observation has been further ratified
by the demonstration of IgE switch circle transcripts in the bronchial mucosa of both
atopic and non-atopic asthmatics but not controls65, confirming that the mucosal
environment in asthmatics is conducive to heavy-chain switching to IgE. This has led to
the hypothesis that the respiratory mucosa is a major site of IgE synthesis127, and that
most of this IgE is sequestered locally bound to high and low affinity IgE receptors,
with circulating IgE representing no more than the “spill over” from this process.
(iv) Cells in the bronchial mucosa of non-atopic as well as atopic asthmatics show elevated
expression of the high-affinity IgE receptor FcRI39. IgE in concentrations above 1
g/ml (an order of magnitude greater than that in normal serum) up-regulate receptor
expression by preventing proteolytic cleavage at the cell surface128. Consistent with the
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effector activity of this IgE, mast cells are seen to be degranulated in the bronchial
mucosa of both atopic and non-atopic asthma patients129.
Given these findings it seems perfectly conceivable that IgE elaborated in the respiratory
mucosa might not escape into the peripheral circulation in sufficient quantities to be
detectable by skin prick or in vitro tests. Furthermore, it is perfectly possible that not all IgE
responses relevant to asthma pathogenesis are directed against allergens. For example, there is
evidence that IgE against respiratory tract viruses130, Staphylococcal superantigens (which has
been shown to cause local oligoclonal activation of mucosal IgE+ B cells34,131) and even
autoantigens132 may play a role in asthma pathogenesis. Finally, certain species of so-called
“highly cytokinergic” IgE can affect the function of mast cells by mechanisms other than
surface cross-linking133,134. All of these observations provide strong support for the hypothesis
that IgE plays a role in the pathogenesis of asthma, regardless of the atopic status of the
patient as defined by positive or negative skin prick tests. A corollary of this hypothesis is that
anti-IgE strategies will be effective in treating patients with non-atopic asthma.
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Fig:1.1058 IgE in the pathogenesis of asthma and allergy and the role of anti-IgE
Notes: IgE is synthesised and secreted by B cells/plasma cells that have undergone heavy-chain class switching
from IgM or IgG to IgE. The IgE binds to Fc RI on mast cells and antigen-presenting cells (APCs) (a) and
sensitizes these cells to allergens. Omalizumab inhibits the binding of IgE to Fc RI on mast cells and APCs (b).
Allergen binding to IgE triggers mast-cell degranulation to cause an allergic response (c) Allergen binding to
the APC leads to the presentation of allergenic peptides to T helper 2 (Th2) cells (d) The allergen-activated Th2
cells secrete interleukin-4 (IL-4) (e) to maintain the Th2-cell lineage and recruit more Th cells into this lineage
(e) The Th2 cells also secrete IL-13 and express CD40 ligand (CD40L), which together with IL-4 stimulates
heavy-chain class switching to IgE (f). The allergen-activated mast cells contribute to the production of IL-4 and
IL-13 (and express CD40L), which may also stimulate heavy-chain class switching to IgE (g). IL-4, IL-13 and
CD40L also stimulate the expression of CD23 and the release of soluble CD23 (h). In humans, soluble trimeric
CD23 up regulates IgE synthesis and secretion through interaction with CD21 (i).
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1.8 Allergen dependent and independent mechanisms of mast cell activation
It is possible that IgE mediates mast cell activation and degranulation in the mucosa of non-
atopic asthmatics by cryptic allergen dependent and independent mechanisms. In the former,
allergen-specific IgE antibodies may be restricted to the bronchial mucosa and therefore not
detected by the conventional skin or serological tests. Alternatively, allergen-independent
mast cell activation by IgE may occur by way of the “cytokinergic” activity of certain IgE
molecules or the activity of free immunoglobulin light-chains.
1.8.1“Cryptic allergen” dependent mechanisms
1.8.1.1 Common allergens:
Estimates of between 20 and 60% of rhinitis patients have IgE antibodies against common
allergens confined to the nasal mucosa according to reports from different laboratories135-138.
The “local IgE” exhibits a higher ratio of allergen-specific to total IgE than that in serum from
the same individual91. Bronchial provocation of atopic asthmatics causes an increase in
allergen-specific IgE in the airways, which is not detected in the circulation139. Together these
observations strongly suggest local generation and sequestration of IgE antibodies to common
allergens at least in atopic patients.
1.8.1.2 Rare allergens:
These are identified allergens but not amongst the small number of common ones tested in the




IgE antibodies directed against auto(self) allergens are observed in atopic dermatitis,
predominantly in patients with severe and chronic disease142. Valenta et al. have determined
their specificities by screening a phage expression library of human cDNAs with IgE from
patient serum. The auto-antigens comprise a wide variety of proteins expressed in unrelated
human cell types and tissues and the reactions in skin are attributed to local tissue damage. It
is possible that auto-allergens may play a similar role in non-atopic asthma143.
1.8.1.4 Anti-IgE or FcRI auto-antibodies
These may mimic allergens by cross-linking IgE bound to FcRI, or the receptor itself, on
mast cells. Such antibodies (generally of the IgG class) induce urticaria by activating skin
mast cells in about 30-40% of patients143-145. Tedeschi et al.146,147 have shown that injection of
autologous serum into the skin of a sub-group of non-atopic asthmatics caused a wheal and
flare reaction. The serum also induced degranulation of basophils from normal donors in
vitro. Anti-IgE or anti-FcRI auto-antibodies may therefore be implicated in non-atopic
asthma148.
1.8.2 Staphylococcus aureus enterotoxins
Staphylococcus aureus is a commensal bacterium that colonises the nasal mucosa
intermittently or permanently in some 60% and 20% of the population respectively149. It may
secrete a range of more than 50 enterotoxins. The “classical” S. aureus enterotoxins A (SEA),
B (SEB), C (SEC), D (SED), E (SEE) (up to U) and Toxic shock syndrome toxin (TSST-1)
act as T cell and/or B cell superantigens which bind to relatively conserved framework
regions of T and/or B cell receptors rather than to the complementarity-determining regions.
Certain superantigens can therefore stimulate the proliferation of a vastly greater proportion
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of B cells than ordinary antigens and cause a cytokine storm in vivo150. Selective
amplification of the “cognate” immunoglobulin families results in characteristic changes in
the immunoglobulin repertoire151. Such changes have been observed in the target organs of
autoimmune and infectious diseases151, allergic rhinitis33,131,152 and asthma100.
1.9 The concept of allergen-exacerbated, non-atopic asthma
Although “non-atopic” patients by definition lack IgE responses to recognised aeroallergens,
it remains possible that the symptomatology, if not the pathogenesis of asthma might be
driven by unidentified allergens as described in the previous sections, where the allergen
cannot be detected in the periphery by skin prick or specific IgE testing. Patients with late-
onset eosinophilic asthma are less often typically “allergic” by conventional criteria5,153-155.
Nevertheless, as elaborated above, many of these patients have elevated levels of total IgE,
and may have IgE responses directed against environmental proteins not conventionally
regarded as allergens, such as Staphylococcal superantigens156,157. In addition, late-onset
eosinophilic asthma is often associated with sensitivity to non-steroidal, anti-inflammatory
medications (aspirin)153,158.
Alarmin-driven mucosal inflammation in asthma may drive the development of IgE against a
wide variety of local antigens, many of which are never looked for in conventional “allergy”
tests. Thus the concept of dividing asthma into “atopic” and “non-atopic” on the basis of a
few, arbitrary skin prick tests may not be entirely accurate. The question is precisely what
role, if any, these IgE molecules play in the propagation of mucosal inflammation and
symptomatology in asthma.
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1.10 Novel allergen independent mechanisms
1.10.1 “Cytokinergic IgEs”
These are a subset of IgEs that activate mast cells in an allergen-independent manner. Their
activities were recently discovered and elucidated by Kawakami et al. in mouse. There are
also a small number of reports of this activity in human systems159,160. The “highly
cytokinergic” murine IgE SPE7 is monomeric in solution but self-associates upon binding to
FcRI on mast cells, thereby activating the cells161-163. It has recently been demonstrated for
the first time that approximately half of the recombinant IgEs derived from the nasal mucosa
of allergic rhinitis patients are highly cytokinergic164. Cytokinergic activity requires relatively
high concentrations of IgE (1-5 g/ml), similar to the concentrations required for up-
regulation of FcRI, as present in the bronchial mucosa in both atopic and non-atopic asthma.
1.10.2 Free immunoglobulin light-chains
These are by products of high-rate immunoglobulin synthesis in B cells. Recent work by
Redegeld et al. has shown that they induce mast cell activation in vitro and in vivo in a mouse
model of asthma165-168. In addition, a 9-amino acid peptide antagonist (F991), which acts as a
competitive inhibitor of light-chain binding to an unknown receptor on mast cells, is
protective in vivo in the mice169,170. The authors suggest that the limited efficacy of
omalizumab in atopic asthma, and the perplexing non-responsiveness of some 30% of all
patients171 , may be partly due to the activities of free light-chains. Omalizumab does not
suppress IgE synthesis172, and therefore synthesis of excess light-chain may continue or even
increase when free IgE is largely neutralised.
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The hypothesis is that IgE is implicated in the pathogenesis of non-atopic asthma by
participating in one or more of above described mechanisms of chronic mast cell activation.
My aim was to analyse some of the above mentioned conceivable mechanisms of mast cell
activation involving IgE, in a group of atopic and non-atopic asthmatics and controls
broadening the fundamental understanding of the potential role of IgE antibodies in non-
atopic asthma and generating further hypotheses concerning novel diagnostic approaches and
therapeutic strategies.
1.11 Omalizumab and its role in asthma treatment
Omalizumab is a humanised, monoclonal IgG1 antibody which binds to the Cε3 constant 
domain of human IgE, blocking binding to both its high- and low-affinity receptors FcεRI and 
FcεRII (CD23)124,126,173,174. It does not cross-link cell surface-bound IgE, which might result
in anaphylaxis. It forms complexes with free IgE in the circulation. Consequently, provided a
sufficient dosage of omalizumab is given, free IgE is reduced in the circulation within a few
days to barely detectable levels (<25 ng/ml). Since free IgE up-regulates the expression of its
own receptor FcεRI, expression of this receptor on mast cells and basophils is reduced over a 
period of months, provided that regular therapy is continued128.
The humanised, monoclonal anti-IgE antibody “omalizumab” is the first major new
development in asthma therapy in nearly 10 years. It has already been used under licence to
treat thousands of allergic asthmatics in many countries. It has been proven to reduce the
frequency of exacerbations in severe allergic asthmatics, resulting in fewer unplanned hospital
visits: a factor most detrimental of all to quality of life based on the results from previous
clinical trials175. Its efficacy and safety are well documented176.
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1.12 Omalizumab clinical trials
i) INNOVATE trial175: This was one of the landmark trials to establish the therapeutic
efficacy of omalizumab in allergic asthma. A total of 419 patients with severe persistent
allergic asthma receiving GINA step 4 treatment were included in the study. The results
revealed that in patients with inadequately controlled severe persistent asthma despite high-
dosage ICS and LABA therapy, and often additional therapy, omalizumab significantly
reduced the rate of clinically significant asthma exacerbations, severe exacerbations and
emergency visits.
ii) In a similar randomized clinical trial177, omalizumab was found to be efficacious in
reducing the numbers of exacerbations suffered by patients with severe, persistent asthma
during a steroid stable phase and a steroid reduction phase. The addition of omalizumab to
standard asthma therapy reduced asthma exacerbations and decreased inhaled corticosteroid
and rescue medication usage. Omalizumab was well tolerated, with an adverse events profile
similar to that of placebo.
iii) The steroid sparing effect of omalizumab was further confirmed in a trial178 where it
reduced the mean exacerbation rate by 52% during a steroid reduction phase and by 58%
during a subsequent steroid stable phase. These data indicated that omalizumab therapy safely
improves asthma control in allergic asthmatics who remain symptomatic despite regular use
of inhaled corticosteroids and simultaneous reduction in inhaled corticosteroid requirement.
iv) The efficacy, safety and steroid sparing effect of omalizumab in allergic asthma were
further confirmed in another clinical trial179 where therapy reduced the inhaled corticosteroid
load of the patients with no deterioration in their symptomatology or increase in the use of
rescue medication.
v) Another interesting and relevant argument gaining popularity lately is that omalizumab
enhances anti-viral immunity by improving the IFN-α response to rhinovirus. Some patients 
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with asthma have reduced antiviral type I and III interferon responses, a defect also noted
with peripheral blood plasmacytoid dendritic cells isolated from asthmatic patients and
associated with IgE concentration on the cell surface180-183. In a randomised controlled trial of
inner city children, omalizumab improved IFN-α responses to rhinovirus, and within the 
omalizumab group, greater IFN-α increases were associated with fewer exacerbations.184
Because of incomplete knowledge of how omalizumab works, it is currently denied to non-
atopic asthmatics, who form about 30% of the total population of adult asthmatics and who
are more likely to have disease uncontrollable by conventional therapy. By this study I wished
to test for proof of principle that omalizumab is of therapeutic benefit to non-atopic
asthmatics, which would open up this therapeutic option to approximately 30,000 more
patients in the UK and many more worldwide.
1.13 Omalizumab in non-atopic asthma
Since omalizumab blocks IgE binding to its receptors, the tacit assumption, yet to be verified,
is that it exerts its anti-asthma effect fundamentally by abolishing allergen-induced mast cell
and basophil degranulation in atopic patients who manufacture allergen-specific IgE (in other
words, it only works on atopic asthmatics). Consequently, to date, trials of its efficacy have
been limited to severe atopic asthmatics with evidence of circulating allergen-specific IgE
production as detected by one or more positive skin prick or in vitro tests. Its licence currently
restricts its use to such patients. Given the possibility that non-atopic asthmatics also make
allergen-specific IgE which is sequestered in the bronchial mucosa, and that many other IgE
species not specific for allergens may play a role in asthma pathogenesis as discussed above,
inhibition of allergen-induced mast cell degranulation may not be the only, or even the
principal mechanism by which omalizumab alleviates asthma. Omalizumab administration
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results in a substantial reduction of free IgE and consequent down regulation of FcεRI. Since 
epidemiological studies have shown that serum concentrations of IgE, regardless of its
specificity, are directly associated with the risk of non-atopic asthma, a reduction of
functionally active IgE may be postulated to be beneficial in non-atopic asthmatics125.
Omalizumab therapy has also been shown to reduce bronchial mucosal inflammation in atopic
asthmatics171,185. The mechanism of this effect (in particular if and how it is related to removal
of IgE) is unknown, but the observation is important since it suggests that, given the
aforementioned evidence, the strategy may be anti-inflammatory in non-atopic, as well as
atopic asthma.
Consequently, I considered it of vital and pressing importance to investigate the therapeutic
potential of anti-IgE therapy in non-atopic asthmatics. Omalizumab is developed and ready
for use, and there is no reason for delay while patients continue to suffer. Its principal benefit,
as mentioned, is in reducing unexpected disease exacerbations186, in patients who continue to
have these exacerbations despite maximal conventional therapy. Since it would require a
large, lengthy and costly clinical trial to demonstrate benefit of omalizumab in terms of
reduction of disease exacerbations in a group of severe non-atopic asthmatics taking maximal
conventional therapy, I determined initially to conduct a proof of concept study powered to
detect differences in clinical and physiological outcome measures between omalizumab and
matched placebo therapy in severe, non-atopic asthmatics whose disease was provoked in the
shorter term by reduction of therapy. I remain hopeful that this will provide sufficient impetus
for more extensive clinical trials and alteration of omalizumab licensing. I also took the
opportunity to measure possible effects of omalizumab on inflammatory cellular infiltration
and IgE expression in the bronchial mucosa of non-atopic asthmatics.
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I conducted a placebo controlled, double blind, parallel group study to test for proof of
principle that omalizumab exerts beneficial effects on disease control in non-atopic moderate
and severe adult asthmatics aged 18-75 years (British Thoracic Society treatment steps 3 and
above). My aim was to recruit and randomise up to forty patients in a 1:1 ratio to receive
omalizumab or matching placebo. Following 12 weeks of treatment with omalizumab or
placebo, existing anti-asthma treatment was progressively reduced while omalizumab/placebo
therapy was continued. Dosages of omalizumab or placebo were administered at 4 or 2
weekly intervals over a 16-week period (5 or 10 doses in total), which corresponded with the
time stated as necessary to judge efficacy of therapy according to omalizumab’s licensed
indications in atopic asthma. Efficacy was judged by clinical monitoring and by bronchial
biopsy to assess effects on bronchial inflammation and IgE expression.
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1.14 Hypotheses of the project
 Allergen-specific IgE is expressed in the bronchial mucosa of non-atopic, as well as
atopic asthmatics.
 In non-atopic asthmatics, IgE has the potential to activate target cells by allergen-
dependent mechanisms involving allergen-specific IgE and by additional, independent
mechanisms mediated by anti-IgE auto-antibody.
 Anti-IgE (omalizumab) therapy reduces bronchial mucosal IgE expression and
inflammation, and improves lung function in the face of staged reduction of
“standard” therapy in non-atopic asthma.
1. 15 Aims and objectives of the project
 To compare changes in lung function, disease control and quality of life as well as
histological indices of inflammation and IgE expression in the bronchial mucosa of a
group of moderate and severe, non-atopic asthmatics treated in a double-blinded
fashion with omalizumab or placebo for the standard period of 16 weeks while
“standard” anti-inflammatory therapy is reduced.
 To measure total and allergen-specific IgE in the bronchial mucosa of atopic and non-
atopic asthmatics and non-atopic controls.
 To investigate the possible effects of anti-IgE autoantibody in promoting and
inhibiting basophil (and putatively mast cell) activation.
72
Chapter 2: Materials and methods
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2. Subjects, materials and methods
2.1 Subjects
Study subjects were identified from the asthma clinics, the departmental database or through
advertisements. Atopic and non-atopic asthmatic patients and non-atopic non-asthmatic
control subjects (non-atopic controls) were identified based on the definitions and criteria
described below. Non-atopic asthmatics were also identified as part of the clinical trial
“omalizumab in non-atopic asthma”.
2.2 Definitions
2.2.1 Asthma
A diagnosis of asthma was made based on relevant symptoms and one of the following criteria
 Documented ≥ 12% reversibility of FEV1 or PEFR in response to inhaled bronchodilators 
(β-agonist and/or anticholinergics)  
 Documented ≥ 20% variability of PEFR readings over a period of 1-2 weeks 
 Documented history of positive bronchial challenge test




Atopy was defined, following worldwide clinical consensus, as positive skin prick test and/or
in vitro IgE test to one or more of the following aeroallergens: mixed grass, mixed tree, mixed
mould, house dust mite, and cat and dog dander.
2.2.3 Non-atopy
Non-atopy was defined as negative skin prick and in vitro IgE tests (Phadia Grade 0 or ≤ 0.35 
kU/L) to the same common aeroallergens.
2.3 General exclusion criteria:
i) Age < 18 or > 75 years
ii) Asthmatics with FEV1 < 40% predicted at the time of study
iii) Patients taking >20mg of prednisolone daily
       iv)        Total smoking history ≥ 10 pack years 
v) Subjects who are pregnant, at risk of pregnancy or lactating
vi) Subjects with any chronic pulmonary, cardiac or other disease
which may compromise the safety of fibreoptic bronchoscopy or
interpretability of the study
vii) Inability or unwillingness to co-operate with the clinical protocol.
2.4 “Omalizumab in non-atopic asthma”- brief summary of the clinical trial
This was a randomised, placebo-controlled, double blind, parallel-group, proof of concept
trial of 20 weeks’ duration. Omalizumab and identical vehicle control manufactured to GCP
standards were kindly supplied by the manufacturers (Novartis Pharmaceuticals). The trial
was approved and monitored by Guy’s Research Ethics Committee (REC Ref: 09/H0804/43)
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and the Medicines and Healthcare Products Regulatory Agency (CTA No:
14523/0219/001/0001) and registered on clinicaltrials.gov (reference NCT01113437). Eligible
patients were moderate/severe, non-atopic asthmatics who provided written, informed consent
recruited from the asthma clinics at Guy’s and St. Thomas’, the Royal Brompton and the
Homerton University Hospitals in London, the departmental database or through
advertisement.
Asthma and non-atopy were defined as described in the earlier paragraphs. Moderate/severe
asthma was defined as regular (at least 3 days per week) day- and night-time symptoms in the
3 months prior to screening despite regular step 3-5 asthma treatment according to the BTS
guidelines187. The non-atopic status of these participants was further confirmed by full ISAC
(Phadia) screening of their sera and bronchial biopsy homogenates (data presented in chapter
4) 188.
Patients in the following categories were excluded from taking part in the trial: i) Smoking
within 3 months prior to screening or total smoking history >10 pack years, ii) Pregnant or
lactating females or those at risk of pregnancy, iii) Patients taking >20mg of prednisolone
daily, iv) Hospitalisation for asthma or exacerbation requiring systemic corticosteroid therapy
within 3 months of the screening visit, v) History of life-threatening asthma, defined as an
asthma episode that required intubation and/or was associated with hypercapnia, respiratory
arrest and/or hypoxic seizures within the 6 months prior to screening, vi) Pre-bronchodilator
FEV1 < 40% predicted, vii) Patients in whom omalizumab therapy was conventionally
contraindicated or should be used with caution according to the omalizumab SmPC.
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The phases of the study protocol are summarised in Figure 2.1.
Figure 2.1: Clinical trial flow chart outlining interventions. Baseline: Time from screening
visit to first bronchoscopy and commencement of omalizumab/placebo (Weeks -4 to 0). Time
A: Time span during which the patients had a second bronchoscopy (Weeks 12 to 14) after
which therapy was reduced. Time B: End of the trial 20 weeks from the first injection of
omalizumab/placebo.
Screening/baseline: After screening, during a baseline period of up to 4 weeks patients were
given and instructed to use, if necessary, a portable peak flow meter (Mini-Wright Standard
EU Scale, SKU: 3103387, Clement Clarke International Limited) and blank diary forms
(Juniper Asthma Control Diary189) in which they documented daily morning and evening peak
expiratory flow (PEF) and day and night symptoms (on a 0-6 scale) until the end of the study.
Existing anti-asthma medication was not changed at this stage but compliance encouraged.
First bronchoscopy and commencement of therapy: At a second visit patients completed a
Juniper Asthma Control Questionnaire189 (ACQ) and mini-Asthma Quality of Life
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Questionnaire190 (mini-AQLQ), then underwent pre-bronchodilator spirometry (Minispir® PC
based Spirometer, Winspiro Pro version 4.1.5 software) prior to the obtaining of 10
technically suitable bronchial mucosal biopsies from the right or left second or third
generation bronchi at fibreoptic bronchoscopy using an Olympus bronchoscope model BF
XT40 OES. 50ml of venous blood were collected during this and the visit for the second
bronchoscopy. Patients then received their first subcutaneous injection of the trial medication
(omalizumab or identical placebo, allocated by the hospital pharmacy using randomisation
tables with the patient and attending physician blinded), the dosage and frequency of which
(either 2 or 4 weekly) were determined as in standard clinical practice based on their initial
body weight and serum total IgE concentration as described in the Omalizumab SmPC.
Where serum total IgE was below the lowest concentration in the SmPC dosing table the
lowest dosage in the table (75 mg every four weeks) was administered. Patients were
observed for 2 hours afterwards. At each subsequent dosing visit, patients were examined
clinically, encouraged to comply with their usual medication and their diary cards collected
and renewed.
Second bronchoscopy: Within a 2-week window between 12 and 14 weeks after
commencement of omalizumab/placebo therapy (Time A, Figure 2.1), lung function was re-
measured and repeat bronchial biopsies obtained as before.
Therapy reduction phase: Patients were instructed carefully how to use a Turbohaler®
device and asked, commencing the day following the second bronchoscopy, to discontinue all
existing inhaled and oral anti-leukotriene or theophylline based anti-asthma medications and
substitute them with regular budesonide/formoterol combination therapy (Symbicort® 100/6
Turbohaler 2 puffs twice daily initially for 4 weeks and further reduced to 1 puff twice daily
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until the end of the trial) with additional terbutaline (Bricanyl® Turbohaler 500 μg/puff) as 
required for immediate relief of symptoms. For patients taking regular additional oral
prednisolone, an attempt was also made progressively to reduce the dosage according to a
predetermined regimen depending on the dosage at entry to the study (Table 2.1).
Omalizumab/placebo therapy was continued for a total of 20 weeks while this new therapeutic
regimen was pursued.
Table 2.1: Protocol for reduction in the dose of prednisolone
End of the study (Time B/20 weeks, Figure 2.1): At their penultimate visit, 20 weeks from
commencement of omalizumab/placebo therapy, patients completed final ACQ and mini-
AQLQ questionnaires then underwent repeat spirometry before being asked to resume their
original anti-asthma therapy. A final visit was arranged 2 weeks later to check the patients’
wellbeing and enquire about any adverse reactions.
At any time during the study, in the event of an asthma exacerbation, defined as a need for







20 15 10 10
17.5 12.5 7.5 7.5
15 10 7.5 7.5
12.5 7.5 5 5
10 7.5 5 5
7.5 5 2.5 2.5
5 2.5 0 0
79
agreed between the patient and the study physician, patients were treated with a 10-day course
of prednisolone 30 mg/day instituted by the study physician. Such patients left the study,
resumed their regular anti-asthma medication and were followed up as necessary.
2.5 Clinical interventions for the mucosal IgE extraction and anti-IgE autoantibody
experiments
Atopic and non-atopic asthmatic patients and non-atopic non-asthmatic control subjects (non-
atopic controls) were recruited based on the definitions and criteria described in sections
2.2.1, 2 and 3. Non-atopic asthmatics were also identified as part of the clinical trial
“omalizumab in non-atopic asthma”. Flexible bronchoscopy was performed as described in
sections 2.4 & 2.6.4, and ten technically suitable biopsies were collected. Three biopsies from
each subject were weighed then snap frozen in liquid nitrogen for protein extraction and
stored at -80 C until analysed. The remaining biopsies were used for other related studies in
the Department. All ten biopsies from some of the patients were weighed and homogenised
for IgE extraction to detect possible biopsy-to-biopsy or site-to-site variability of IgE
concentrations. 50 ml of venous blood were collected from each subject on the same day as
bronchoscopy, allowed to clot on glass and centrifuged to isolate serum which was stored at
-80°C until analysed.
2.6 Clinical interventions and assessment tools
2.6.1 Skin Prick testing
Standard skin prick tests were performed to investigate sensitisation to a full range of local
aeroallergens. The participants were asked to discontinue any antihistamines they have been
taking for at least 3 days prior to skin prick testing. Skin prick tests were performed on the
volar aspect of the forearm using standard solutions (Diagenics/Allergopharma) such as tree
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mix (early & mid-blossoming including alder, hazel, poplar, elm, willow, birch, beech, oak
and plane), grass mix (velvet grass, cocksfoot, ryegrass, timothy, meadow grass and meadow
fescue), house dust mite mix (Dermatophagoides pteronyssinus & Dermatophagoides
farinae), mould mix (Alternaria tenuis, Botrytis cinerea, Cladosporium herbarum, Curvularia
lunata, Fusarium moniliforme, Helminthosporium halodes, Aspergillus fumigatus, Mucor
mucedo, Penicillium notatum, Pullularia pullulans, Rhizopus nigricans, Serpula lacrymans),
cat epithelia and dog epithelia. The positive and negative controls were histamine (0.1%) and
normal saline respectively. Tests were read after 15 minutes to look for a wheal and flare
response. Any wheal 3 mm larger than the negative control in the presence of a clearly
positive (histamine) control surrounded by a flare was defined as positive. Equivocal results
were cross-checked and verified by looking for specific IgE antibodies in the serum using
Phadia ImmunoCAP®.
2.6.2 Spirometry
Spirometry was performed using Minispir® PC based Spirometer (Winspiro Pro version 4.1.
5 software) according to the guidelines published by the American Thoracic Society and
European Respiratory Societies. Bronchodilator reversibility was assessed after nebulisation
with 2.5 mg of salbutamol and 500µg of ipratropium.
2.6.3 Mannitol Bronchial Challenge Test
Mannitol bronchial challenge test was performed using the OsmohaleTM kit (Pharmaxis
Pharmaceuticals Ltd, Buckinghamshire, UK), following the instructions from the
manufacturer191 and guidelines published by ATS/ERS task force192. Following withdrawal of
relevant medications, a ≥15% fall in FEV1 from baseline or a ≥10% incremental fall between 
the mannitol dosages was considered to be a positive result. Bronchial challenge was not used
81
as a screening tool in the Omalizumab clinical trial to recruit moderate/severe non-atopic
asthmatics.
2.6.4 Bronchoscopy
Flexible bronchoscopy was performed using an Olympus bronchoscope model BF XT40 OES
in accordance with the departmental standard operating procedure. Ten technically suitable
biopsies were collected using FB35C reusable or some similar non-reusable forceps from the
right or left second and third generation bronchi.
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2.7 Laboratory and in vitro procedures
2.7.1 Processing and storage of clinical samples
2.7.1.1 Bronchial biopsies
Bronchial biopsies were collected into separate small polystyrene containers (Bijou bottles)
containing normal saline. Three biopsies were snap frozen in liquid nitrogen for protein (IgE)
extraction, and stored at -80C. Three biopsies were later processed for immunohistochemical
and immunofluorescence experiments as described in sections 2.7.2, 2.7.2.1 and 2.7.2.2. The
remaining biopsies were used for other projects within the Department.
2.7.1.2 PBMC isolation
The following steps were performed at room temperature:
40 ml of blood were diluted with an equal volume of sterile PBS and the mixture divided
between two 50 ml Falcon tubes. 12.5 ml of Ficoll was placed into 50 ml falcon tubes (4 x for
80 mL diluted blood, 2x for 40 mL diluted blood). 20 ml of diluted blood were slowly and
carefully layered onto 12.5 ml Ficoll inside the Falcon tube. The Falcon tubes were then
centrifuged at 2000 rpm for 20 minutes at room temperature without braking. A total of 2 ml
of plasma (top layer) was removed and aliquoted into cryovials. These were placed in a
freezing container overnight before transferring to liquid nitrogen. Lymphocyte layers were
removed and pooled into a new 50 ml Falcon tube and made up to 50 ml with PBS. The tubes
were spun at 2000 rpm for 10 minutes. The cell pellet was re-suspended in approximately 10
ml of PBS. Falcon tubes were then topped up with PBS and centrifuged at 2000 rpm for
10min and the supernatant removed. The cells were then frozen in 10% DMSO (made with
FCS) and placed in a freezing container overnight before transferring to liquid nitrogen. 1x107
cells were prepared per cryovial.
83
Cell counting and viability
A 1:5 dilution was made with 20L cell suspension from the pellet and 80L of PBS. Cells
were counted using a haemocytometer by adding an equal volume of trypan blue solution.
2.7.1.3 Serum preparation
A total of 10 ml blood from each patient were divided between two 5ml serum separating
tubes (BD Vacutainer® SST™).
 Tubes were inverted several times immediately and then kept upright at room
temperature for 30min (2hrs max).
 The tubes were then centrifuged for 10 minutes at 2000g to remove debris.
 1ml of serum supernatant was aliquoted into cryovials and then placed in a freezing
container overnight before transferring to liquid N2.
2.7.2 Immunohistochemical techniques
Bronchial biopsies were processed and analysed using double immunofluorescence, single
immunohistochemistry and confocal microscopy. Bronchial biopsies were fixed in 4% PFA
for 2 hours at room temperature, washed overnight in PBS containing 15% sucrose, embedded
in O.C.T. compound (Tissue-Tek®, VWR International LLC) and stored at -80C. Eight
micron thick sections were cut using a cryostat (Bright OTF 5000, Bright Instruments Co
Ltd), air dried overnight onto Polysine slides (Thermo Scientific) and stored at -800C.
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2.7.2.1 Immunofluorescence
PFA fixed sections were thawed at room temperature for 30 minutes and rehydrated in PBS
for 5 minutes. Total tryptase+ mast cells, CD20+ B cells and CD138+ plasma cells, CD38+
plasmablasts, IgE+ cells and cells of these phenotypes co-expressing IgE were sought and
enumerated from digital images of the sections by two observers ignorant of the origin of the
sections, using single and double immunofluorescence and confocal microscopy. Sections (18
sections per subject: 9 at baseline and 9 at time A) were stained with primary antibodies
diluted in PBS containing 1% normal human serum and 1% normal goat serum (antibody
buffer) or PBS/0.1% saponin for anti-CD20cy [mouse anti-CD138 (1:50; Dako), mouse anti-
human CD38 (1:100, Abgent), mouse anti-human tryptase (1:100, Dako), mouse anti-human
CD20cy (1:120, Dako), and rabbit anti-IgE (1:500, Dako)] and incubated overnight at room
temperature. Excess antibodies were washed off in PBS (5 min X 3 times), then the sections
incubated with anti-mouse-IgG-FITC (1:200; Life Technologies) and anti-rabbit-IgG-Alexa
Fluor 594 (1:200; Life Technologies) diluted in antibody buffer for 1 hour at room
temperature in the dark. After washing with PBS, the sections were mounted with Prolong
Gold Antifade Reagent with Dapi blue nucleic acid background stain (Life Technologies).
The images were captured using a Nikon Eclipse Ti-E inverted confocal microscope (Nikon
Imaging Centre, King’s College London). The images were processed under identical
conditions of illumination using ImageJ (http://rsb.info.nih.gov/ij/) and the total numbers of
positively stained cells (green fluorescing CD20+, CD138+ and tryptase+ cells and red
fluorescing plasmablasts, IgE+ cells and those expressing both red and green fluorescence
measured confocally) counted and expressed as per mm2 of the entire area of the submucosa.
The typical mean co-efficient of variability between the sections was 67.46% for tryptase+
mast cells and 93.01% for CD138+ plasma cells.
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2.7.2.2 Immunohistochemistry
Bronchial biopsies were fixed, frozen and stored as described in the immunofluorescence
section. Total BMK-13+ cells were sought and enumerated using single
immunohistochemistry and confocal microscopy. Sections were stained with BMK-13 (1:30,
Abcam) diluted in PBS containing 5% normal human serum and incubated overnight at room
temperature. Excess antibodies were washed off in PBS (5 min x 3 times), then the sections
incubated with rabbit-anti mouse secondary antibody (1:50, Dako) in PBS containing 5%
normal human serum for 30 minutes at room temperature in a humidifier chamber. After
washing with PBS, the sections were incubated with mouse - APAAP (1:30, AbD Serotec) in
PBS containing 5% normal human serum for 30 minutes at room temperature and then
washed again with PBS (5 min x 3 times). Fast Red solution, prepared by dissolving Fast Red
tablets (Sigma) in dH2O, was applied to the sections for 20 minutes or until a suitable colour
change was observed under the microscope. The Fast Red reaction was stopped with H2O for
5 minutes. Haematoxylin was applied for 30 seconds, and then rinsed off under running water
for 5 minutes. The slides were then dried for an hour, mounted with Glycerol Gel (Dako) and
dried overnight. The images were captured using Nikon Eclipse Ti-E inverted confocal
microscope (Nikon Imaging Centre, King’s College London). The images were processed
under identical conditions of illumination using ImageJ (http://rsb.info.nih.gov/ij/) and the
total numbers of BMK-13 positively stained cells (red colour) counted and expressed as per
mm2 of the entire area of the submucosa.
Primary, secondary and tertiary antibodies used in the immunohistochemical and
immunofluorescence experiments, their respective dilutions, source and catalogue numbers




Antibody Source Dilution Origin/Catalogue no.
Primary Antibodies
Monoclonal Anti-Human Mast cell
Tryptase Mouse 1:100 Dako, M7052
Monoclonal Anti-Human CD138
(Plasma cells) Mouse 1:50 Dako, M7228
Monoclonal Anti-Human CD20cy (B
cells)
Mouse 1:120 Dako, M0755
Monoclonal Anti-Human CD38 Mouse 1:100 Dako, M7254
Polyclonal Anti-Human IgE Rabbit 1:500 Dako, A0094
Secondary Antibodies
Fluorescein F(ab')2 Fragment of Anti-
Mouse IgG (H+L)
Goat 1:200 Life Tech, F11021
Alexa Fluor® 594 Anti-Rabbit IgG
(H+L) Antibody




Monoclonal Anti-Human Mast cell
Tryptase Mouse 1:100 Dako, M7052
Monoclonal [BMK13] to PRG2
Mouse 1:30 Abcam, AB77842
Monoclonal Anti-Human CD138
(Plasma cells) Mouse 1:50 Dako, M7228
Monoclonal Anti-Human CD20cy (B
cells) Mouse 1:120 Dako, M0755
Secondary Antibody
Anti-mouse immunoglobulins,
absorbed Rabbit 1:50 Dako, Z025902-2
Tertiary Antibody
APAAP Complex Mouse 1:30 AbD Serotec,
STAR67
88
2.7.3 Protein extraction from bronchial biopsies
The purpose of these experiments was to attempt directly to measure bronchial mucosal total
and allergen specific IgE.
2.7.3.1 Homogenisation of bronchial mucosal biopsy samples
The biopsies were weighed before homogenisation. The frozen biopsies were pulverized into
a fine powder using a commercial cell crusher (Figure 2.2; Cell crusher/homogeniser, Stratech
Scientific UK Ltd). The powdered tissue was then dispersed in ice cold lysis buffer (30 µl/mg
of tissue). This was prepared by dissolving 0.48 g of TRIS (Sigma Aldrich®) and 0.877 g of
NaCl (Sigma Aldrich®) in 70 ml of distilled water and then adjusting the pH to 7.5 by adding
hydrochloric acid. 1ml of 0.5M EDTA (Sigma Aldrich®) and 1g of CHAPS (Thermo Fisher
Scientific Inc., IL, USA) were added to the above solution and the final volume made up to
100 ml by adding more distilled water. Protease inhibitor cocktail (100X, Pierce Thermo
scientific) was added to the lysis buffer mixture at a volume ratio of 1:100. The suspensions
were vortexed for 30 seconds then homogenised with a Sigma handheld homogeniser (10
times) and incubated on ice for 20 min. The lysed suspensions were then homogenised again
(10 times) then incubated again on ice for 20 min. Finally, they were sonicated in a water bath
for four 5 second periods separated by 30 second intervals then incubated on ice for 20 min.
They were finally centrifuged at 13000 rpm at 40C for 30 minutes, then transferred (diluted, if
appropriate depending on the final volume of the homogenate and the volume required for the
assay, in lysis buffer without CHAPS) into separate clean tubes.
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Figure 2.2: Cell crusher/homogeniser- Stratech Scientific Ltd
Prior to analysis, CHAPS detergent was removed from the samples using Pierce detergent
removal spin columns (Thermo Fisher Scientific Inc., IL, USA). The homogenates (about 200
µl) were finally concentrated by ultra-filtration using Vivaspin2 spin columns (Molecular
weight cut-off 3 KDa, Sartorius Stedim Biotech, UK Ltd, 500 µL-2 ml) and centrifuged at
4000 rpm for 20 min producing a final volume of approximately 50 µl. Concentrated
homogenates were aliquoted and stored on ice for immediate analysis or at -80 C for later
analysis.
2.7.3.2 Total IgE estimation by ImmunoCAP 100
ImmunoCAP provides an in vitro test for quantitative measurement of the total amount of
circulating IgE in human serum or plasma samples. In addition, we developed the technique
to measure IgE in tissue homogenates in this project.
2.7.3.2.1 Test Principle
The technology is based on provision of an extremely high total binding capacity on a
cellulose substrate. This ensures binding of all relevant antibodies, regardless of affinity while
minimising non-specific binding. The ImmunoCAP solid phase consists of a cellulose
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derivative enclosed in a capsule. The hydrophilic, highly branched polymer provides an ideal
microenvironment for antigen/antibody interactions. The protocol was designed as a sandwich
immunoassay as outlined in Figure 2.3.
2.7.3.2.2 ASSAY PROCEDURE
The IDM (ImmunoCAP 100E) machine and associated software were started and the total IgE
assay run according to the manufacturer’s instructions. (A detailed standard operating
procedure for this assay is included in Appendix1. The steps are outlined below).
The caps were removed on the reagents and samples before placing them in the sample
carousel. It was ensured that there was sufficient volume of samples and reagents to be drawn
into the machine. Air bubbles or film on the surface of the reagents/samples were removed as
otherwise the pipette sensor will not detect the surface properly. Washing, rinse and waste
bottles were also loaded beforehand. About 50µL of each sample were loaded and placed on
the loading slots as the carousel moved to the next position. All the required controls were
loaded. Then all the required reagents (i.e. total IgE conjugate, development solution, stop
solution, etc.) were added in the given positions. The next step was to start loading the
ImmunoCAP /EliA Wells and a blank check. After the blank check was completed, the
appropriate ImmunoCAP /EliA Wells were loaded in the dispenser when requested. The Lot
Specific Code found on the label on the EliA Well foil bag and on the EliA Well Carrier was
entered. When all ImmunoCAP/EliA Wells were loaded, the carrier was removed and the
assay run process started. The IDM machine is configured to run automatically when primed.
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Figure 2.3: ImmunoCAP for total IgE - test principle
After washing the second layer,
enzyme-conjugated anti-IgE
antibodies are added to form a
complex.
After incubation, unbound enzyme-
labelled anti-IgE is eluted and the
bound complex incubated with a
developing agent.
After stopping the reaction, the fluorescence
of the developed reagent is measured.
The fluorescence is proportional to the
concentration of IgE in the serum sample
and calibrated using a reference sample.
Anti-IgE, covalently coupled to the
solid phase, reacts with the total IgE
in the patient serum sample
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2.7.3.3 Measurement of specific IgE to multiple allergen components using Phadia
ImmunoCAP ISAC® Micro Array
2.7.3.3.1 ImmunoCAP ISAC (Immuno Solid Phase Allergen Chip) is a diagnostic test
using biochip technology. It allows simultaneous measurement of specific IgE antibodies to
multiple allergen components in a single test, using only as little as 20 µl of the biological
sample. The specific IgE chip delivers results for over a hundred components from more than
50 allergen sources. The allergens are pre-selected and include the most relevant species
specific and cross-reactive markers but not necessarily every allergen component to which the
patient may be sensitised.
2.7.3.3.2 Principles of the procedure
ImmunoCAP ISAC is a solid-phase immunoassay. Allergen components immobilised on a
solid substrate in a microarray format are incubated with human biological samples to detect
specific IgE antibodies. Binding of the specific IgE antibodies to the immobilised allergen
components is detected by the addition of a secondary fluorescence-labelled anti-human IgE
antibody. The procedure is followed by image acquisition using an appropriate microarray
scanner. The ISAC Standardized Units for specific IgE (ISU) are determined and the test
results analysed with proprietary software (MIA - Microarray Image Analysis Software). An
outline of the test is presented in Figure 2.4 and detailed protocol in Appendix 2.
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Figure 2.4: ImmunoCAP ISAC test outline
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2.7.3.3.3 Reagents
ImmunoCAP ISAC Assay Kit IgE and ImmunoCAP ISAC Starter Kit IgE contain the
reagents required to perform the assay. (More under protocol later: Appendix 2).
2.7.3.3.4 Specimens
Sera and bronchial biopsy homogenates from the participants were analysed. Blood samples
were collected using standard procedures. The biopsy homogenates were concentrated using
Vivaspin-2 (MWCO 3000). Specimens were stored at 2 – 8°C for up to one week or at –20°C
for prolonged periods. Repeated freezing and thawing were avoided.
2.7.3.3.5 Protocol
35 ml of component A were added to 665 ml of purified water to prepare 700 ml of freshly
prepared solution A (1:20 dilution). This volume was calculated for 3 washing steps of 220 ml
each, using the washing dishes provided with the starter kit. A fresh paper towel was placed at
the bottom of the humidity chamber and soaked with purified water. The lid of the humidity
chamber was closed until further use to prevent evaporation. ImmunoCAP ISAC chips were
placed in the washing dish containing the removable glass slide rack and approximately 220
ml of solution A together with a magnetic stirring bar and the solution stirred vigorously for
60 minutes on a magnetic stirrer. The glass slides containing the ImmunoCAP ISAC were
moved into another washing dish containing approximately 220ml of purified water and
stirred vigorously again for 5 minutes. They were then placed on a paper towel and left to air
dry completely. The prepared ImmunoCAP ISAC slides were then placed in the humidity
chamber with the reaction sites facing upwards. 20 µL of samples were pipetted onto each of
the reaction sites (4 reaction sites per slide) while avoiding any direct contact of the pipette tip
with the surface of the slides. The slides were then carefully placed in the humidity chamber
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without mixing the samples and the lid closed. Incubation was allowed to proceed at room
temperature for 120 minutes. The slides were removed from the humidity chamber carefully,
without mixing the samples. The residual fluid was removed by tapping the chip with its long
side on a fresh paper towel, taking care to avoid samples running over the neighbouring
reaction sites. The ISAC chips were then washed in 220 ml of solution A for 10 minutes
followed by 220 ml purified water for 5 minutes using the washing dish and magnetic stirrer
as described previously. The washed slides were allowed to air dry completely and then
placed in the humidity chamber with the reaction sites facing upwards. All used washing
solutions were discarded. 20 µL of the IgE detection antibody solution were then pipetted
onto each reaction site of the ImmunoCAP ISAC. ISAC slides were then replaced in the
humidity chamber and incubated at room temperature for 60 minutes with lid closed to protect
from light. The slides were then removed from the humidity chamber carefully and the IgE
detection antibody solution removed by tapping the slide with its long side on a fresh paper
towel or rinsing gently under distilled water. The slides were then washed in approximately
220 ml solution A for 10 minutes and then in 220 ml of distilled water for 5 minutes, using
the washing dish and magnetic stirrer. All used washing solutions were discarded. The
washed slides were allowed to air dry completely and thus become ready for reading. They
were directly read in an appropriate microarray scanner or stored dry and protected from light
for subsequent reading.
2.7.3.3.6 IgE recovery during extraction
In order to determine the recovery of IgE during the homogenisation and extraction processes,
total and allergen specific IgE estimations were performed using the same assays
(ImmunoCAP and ISAC) at each step of the extraction on tissue samples (and sera) from
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some of the subjects. The IgE extraction experiments were also repeated using IgE standards
of known concentrations and Phadia ISAC IgE control antibody at each step.
2.7.3.3.7 Variability between biopsies
In order to estimate the variability of mucosal IgE concentrations between different sites in
the bronchial tree, total IgE was measured in 10 separate biopsies taken from the upper,
middle and lower 1st -3rd generation bronchi from a single atopic asthmatic subject as
described above.
2.7.4 Anti-IgE autoantibody experiments
Atopic asthmatic (AA), non-atopic asthmatic (NAA) and non-atopic non-asthmatic control
(NAC) subjects were recruited as described in sections 2.2 and 2.3. Serum separation and
PBMC isolation were performed as described in sections 2.7.1.2 and 2.7.1.3. All participant
sera were screened for anti-nuclear autoantibodies (ANA) using commercially available
ANA-ELISA kits (Abnova, Taiwan) according to the manufacturer’s instructions.
2.7.4.1 ELISA
Maxisorp plates (Thermo Fisher Scientific) were coated either with 0.5 μg/mL of recombinant 
IgE (Abcam, Cambridge, UK) to measure IgG anti-IgE, or anti-human IgG (diluted 1:1000;
AbD Serotec, Oxford, UK) to measure total IgG, in 50mM carbonate buffer pH 9.6 at 4°C
overnight. Non-specific binding was blocked with SuperBlock blocking buffer (Thermo
Fisher Scientific) or 3% milk powder (MP) in PBS-T at room temperature (RT) for 2 hours,
and the plates then washed three times with PBS-T. Test sera were added at 1:5 to 1:20
dilutions in 1% MP-PBS-T and the plates incubated at RT for 1 hour, then washed three times
with PBS-T and incubated with anti-human IgG-HRP (diluted 1:10000 in 1% MP-PBS-T;
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Sigma-Aldrich, MO, USA) for 1 hour at RT. The plates were washed again 3 times and the
colour reaction developed using TMB solution (R&D Systems). The reaction was stopped by
addition of 1.8M H2SO4 and absorbance read at 450 nm using a Multiskan EX plate reader
(Thermo Fisher Scientific). The assay was calibrated using a commercial IgG anti-IgE
monoclonal antibody (omalizumab; Novartis, UK) or human IgG (Sigma-Aldrich). All
samples were measured at least in duplicate. To further allow for any non-specific IgG
binding to the plates and determine the threshold of sensitivity of the anti-IgE ELISA (0.27
ng/mL), commercial human IgG (Sigma-Aldrich) was used at a relatively high concentration
(2 μg/mL) in place of sera as a negative control and the threshold defined as 3 standard 
deviations above the mean resulting absorbance.
The binding of IgG anti-IgE autoantibodies to FcεRI-bound IgE was determined by pre-
coating the ELISA plate with recombinant FcεRIα (0.5 μg/mL; R&D Systems) in carbonate 
buffer at 4°C overnight. After washing 3 times with PBS-T and blocking with 3% MP in
PBS-T for 2 hours at RT, the plates were incubated overnight at 4°C with recombinant IgE
(0.5 μg/mL in 1% MP in PBS-T). Plates were washed 3 times with PBS-T before the addition 
of the test sera and the assay developed as described above. Each sample was assayed at least
in duplicate.
2.7.4.2 Basophil activation test (BAT) by flow cytometry
Peripheral blood mononuclear cells (PBMC) from a single atopic non-asthmatic donor with
total serum IgE > 150 IU/mL and sensitised to house dust mite as determined by skin prick
testing were isolated using Ficoll-Paque PLUS (GE Healthcare) and re-suspended in HBSS
(Sigma-Aldrich) to a final concentration of 2x107 cells/mL.
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To test the activity of subject sera in the BAT assay, 1x106 PBMC (50 L of suspension) were
incubated with sera diluted 1:2 in BAT buffer to 50 μL (HBSS with 2mM CaCl2) for 30 min
at 37°C and the reaction stopped by adding 2 mL of FACS buffer containing 2mM EDTA on
ice. The donor’s own serum was used as a baseline control. As a positive control, instead of
sera, PBMC were activated using polyclonal anti-IgE (Dako, Glostrup, Denmark) in the
concentration range 6 ng/mL to 6 g/mL in BAT buffer.
Flow cytometric analysis of basophil activation was adapted from a previously published
protocol193. PBMC were stained with anti-CD203c-phycoerythrin (Clone NP4D6; BioLegend,
CA, USA) and anti-CD63-allophycocyanin (Clone MEM-259; BioLegend) using the
manufacturer’s recommended concentrations in FACS buffer (PBS containing 2% FBS) for
30 min on ice, washed in FACS buffer and analysed using a BD FACSCalibur (BD
Biosciences). Basophil activation was defined as the percentage of CD203c+ basophils
expressing the activation marker CD63 compared with the baseline control.
2.7.4.3 Allergen-induced basophil activation
To determine the effect of subjects’ sera on allergen-induced basophil activation, we pre-
incubated 106 PBMCs in 50 L of BAT buffer from a single atopic donor sensitised to house
dust mite with the sera (diluted 1:2 in BAT buffer to 50 L), purified anti-IgE, or the donor’s
own serum as a baseline control for 30 min at 37°C. The cells were then washed and
resuspended in 50 L BAT buffer prior to the addition of serial dilutions of the major HDM
antigen Der p2 from 300 to 3 ng/mL for 30 min at 37°C. The reactions were stopped by
adding 2 mL of FACS buffer containing 2mM EDTA on ice, and basophil activation
determined as described above.
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2.7.4.4 Depletion of total IgG and IgE binding proteins from sera
To deplete total IgG from sera, 500 μL samples were incubated with an equal volume of 
protein G Sepharose (Sigma-Aldrich) at 4°C overnight in a mini Bio-Spin chromatography
column (Bio-Rad, CA, USA). The flow through was recovered and re-incubated with fresh
protein G Sepharose at 4°C overnight. IgG was measured in the final recovered flow through
by ELISA.
To deplete IgE-binding proteins, IgE was cross-linked to cyanogen bromide (CNBr)-activated
Sepharose 4B (Sigma-Aldrich) according to the manufacturer’s instructions. Briefly, 100 μg 
of recombinant IgE anti-NP-BSA (manufactured in-house) was mixed with 100 μL of 1mM 
HCl-swollen CNBr-activated Sepharose in coupling buffer (0.1M NaHCO3 buffer containing
0.5M NaCl) at 4°C overnight a mini Bio-Spin chromatography column, then washed with
coupling buffer. Unconjugated sites were blocked with 0.2 M glycine buffer pH 8.0 for 2
hours at RT. After extensive washing with 5 cycles of the coupling buffer and 0.1M acetate
buffer pH 4, the IgE-coupled Sepharose was ready to be used. IgE-coupled Sepharose (50 μL) 
was mixed with subjects’ sera (3 mL) at 4°C overnight. The eluate containing non-IgE
binding antibodies was stored at -20°C for later analysis. Proteins bound to the IgE-coupled
Sepharose were then eluted with 100 μL of 0.2M glycine pH 2.5 into an equal volume of 
100mM Tris buffer pH 8.0. The eluted solutions were dialysed in PBS at 4°C overnight, then
mixed with protein G Sepharose (1:1) at 4°C overnight to capture IgG antibodies. The IgG
anti-IgE antibodies were eluted off the protein G Sepharose with glycine, dialysed with PBS
as above then quantified by ELISA and run on 10% SDS-PAGE under non-reducing
conditions compared with recombinant IgE and IgG (Sigma-Aldrich). No contaminating IgE
was found in purified antibodies as determined by total IgE ELISA (Figure 5.6, individual
data not shown).
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2.7.4.5 Effects of sera on allergen binding to IgE-bound basophils
To determine the effects of our test sera on allergen binding to IgE on the surface of
basophils, we used pure, recombinant Phl p7-specific IgE sub cloned from an existing IgG4
clone isolated in house194 by replacement of the Cγ4 constant region with that of IgE195. Cells
of the RBL-SX38 rat basophilic cell line, which stably express human FcεRI196, were cultured
in RPMI-1640 medium (Sigma-Aldrich) containing 10% FBS (Sigma-Aldrich), 1%
Penicillin-Streptomycin-Glutamine (Life Technologies, CA, USA) and 1 mg/mL Genticin
(Life Technologies). RBL-SX38 cells were harvested and resuspended in BAT buffer at 2x107
cells/mL then incubated with Phl p7-specific IgE at a concentration of 0.5 μg/mL in 50 μL 
BAT buffer for 30 min at 37°C. Aliquots of 106 cells were washed with HBSS and incubated
with 50 μL aliquots of the sera (diluted 1:2 in BAT buffer) for 30 min at 37°C. After further
washing with HBSS, the cells were resuspended and incubated with 50 μL of 1 μg/mL of in 
house produced, freshly biotinylated Phl p7 diluted in BAT buffer for 30 min at 37°C.
Surface bound IgE was detected using anti-IgE-FITC (Vector Laboratories, CA, USA) and
Phl p7 binding to this IgE using streptavidin-APC (BioLegend), with analysis by flow
cytometry.
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Chapter 3: Effects of omalizumab on lung function, bronchial




Asthma remains a leading cause of suffering affecting about 300 million people worldwide197.
In the UK, 10% of the 5.2 million sufferers are estimated to retain daily symptoms and remain
vulnerable to acute exacerbations despite the regular and efficient delivery of conventional
anti-asthma therapy, including systemic corticosteroid198.
The humanised, monoclonal IgG1 anti-IgE antibody omalizumab is the vanguard of what will
hopefully form an arsenal of new biologicals able to improve the lives of severe asthma
sufferers. That omalizumab therapy stabilises asthma control, reducing disease exacerbations,
and consequently unplanned hospital admissions and exposure to systemic corticosteroid
therapy in a substantial proportion of severe asthmatics is now acknowledged by professional
and regulatory authorities worldwide, including the British Thoracic Society (BTS) and
NICE199 in the UK.
A major challenge when deploying treatment with biologicals for severe asthma is the
possibility of mechanistic variation in the disease, requiring pre-identification of potential
responders to any specific agent. This has generated intense interest in identifying
“phenotypes” or “endotypes” of asthma. In the case of omalizumab, the prima facie effect of
which is to prevent, and possibly reverse binding of IgE to its high- and low-affinity
receptors200,201, the tacit assumption has been that it improves asthma stability fundamentally
by reducing or abolishing mast cell and basophil activation by cross-linking of surface-bound
allergen-specific IgE by allergen in suitably sensitised, “atopic” patients. Consequently, key
clinical trials investigating its efficacy, such the INNOVATE study175 have been limited to
atopic asthmatics while its marketing authorisation restricts its use to patients with
“convincing IgE-mediated asthma”. This phrase is not universally defined but is in practice
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usually equated with evidence of IgE sensitisation (by skin prick or in vitro testing) to one or
more common perennial aeroallergens. Conversely, the therapy has been denied to at least, we
estimate, 20,000 otherwise eligible non-atopic severe asthmatics in the UK, and many more
worldwide (the prevalence of non-atopic, severe asthma was estimated at 50% of the total in
the ENFUMOSA cross sectional study27 and 17–34% in the SARP study)18.
Much indirect evidence suggests that IgE may play a role in asthma regardless of
conventional atopic status. Epidemiologically, asthma was 5 fold more prevalent in a cohort
of non-atopic subjects with elevated total serum IgE125. Many studies have shown that atopic
and non-atopic asthma are virtually identical in terms of their bronchial mucosal cellular and
molecular immunopathology118-124,202, evidence of local B cell switching to IgE synthesis53,203,
elevated local FcRI receptor expression39 (local IgE up regulates FcRI on expressing cells)
and, very recently, elevated total bronchial mucosal IgE concentrations188. Furthermore, there
is ample evidence that IgE directed against antigens other than aeroallergens, such as viral
antigens130 and Staphylococcal enterotoxins204 which also act as superantigens, may play a
role in asthma pathogenesis. IgE may influence the functions of mast cells by antigen-
independent mechanisms133,205. Finally, IgE may exacerbate asthmatic bronchial mucosal
inflammation by mechanisms other than causing degranulation of mast cells and basophils,
such as by enhancing antigen capture by antigen-presenting cells and activating
monocyte/macrophages206. Some patients with asthma have impaired, innate antiviral type I
and III interferon responses, a defect also noted with peripheral blood plasmacytoid dendritic
cells isolated from asthmatic patients and associated with IgE cross-linking on the cell
surface180-183. In a randomised controlled trial of treatment of asthma in inner city children,
omalizumab compared with placebo improved IFN-α responses to rhinovirus, which was 
associated in turn with fewer exacerbations184. Therefore, one of the fundamental effects of
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anti-IgE therapy may be to restore, or at least greatly improve anti-viral immunity by reducing
IgE-mediated inhibition of immune interferon  and  production by innate DCs in the
respiratory epithelium, thus reducing damage to the epithelium, local alarmin production and
up-regulation of Th2-type immunity, leading potentially to further IgE synthesis and a
“vicious cycle” of increased IgE further impairing anti-viral defence. Presumably all of this is
completely independent of conventional atopic status.
All of these data lend weight to the view that the presence or absence of atopy as
operationally defined might not be an appropriate phenotypic or endotypic criterion for
predicting responsiveness to omalizumab therapy.
To address this, I hypothesised that omalizumab therapy provides clinical benefit in chronic,
severe asthmatics designated non-atopic by conventional criteria. Rather than embarking on a
large, lengthy and costly clinical trial with frequency of exacerbations as a primary outcome
measure, I elected in the first instance to provide proof of concept in a double-blind, placebo
controlled study that omalizumab therapy can maintain or improve lung function in these
patients despite provocation of the disease in the shorter term by supervised reduction of
therapy. I also sampled their bronchial mucosa at fibreoptic bronchoscopy before and after
therapy to address the hypothesis that omalizumab reduces local expression of IgE as well as
the numbers of B cells, plasma cells and mast cells.
3.2 Subjects, materials and methods
3.2.1 Subjects
Eligible patients with moderate/severe, non-atopic asthma who provided written, informed
consent were recruited from the asthma clinics at Guy’s and St. Thomas’ Hospital, with the
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intention of supplementing this recruitment through collaboration with physicians in the
asthma clinics at the Royal Brompton and the Homerton University Hospitals in London, and
also from the departmental database or through advertisement.
3.2.2 Definitions
3.2.2.1 Asthma
A physician, based on relevant symptoms and one of the following criteria, made the
diagnosis of asthma:
 Documented ≥ 12% reversibility of FEV1 or PEFR in response to inhaled 
bronchodilators (β-agonist and/or anticholinergics)  
 Documented ≥ 20% PEFR variability over a period of 1-2 weeks 
Moderate/severe asthma was defined as physician diagnosed asthma with regular (at least 3
days per week) daytime and night-time symptoms in the 3 months prior to screening despite
taking inhaled and/or oral corticosteroid with or without long-acting β2-agonist or leukotriene 
blockers (regular step 3-5 asthma treatment according to the BTS guidelines187).
3.2.2.2 Non-atopy
Non-atopy was defined as negative skin prick and/or in vitro IgE tests (Phadia Grade 0 or ≤ 
0.35 kU/L) to the following aeroallergens: mixed grass, mixed tree, mixed mould, house dust
mite, and cat and dog dander.
The non-atopic status of these participants was further confirmed by full ISAC (Phadia)
screening of their sera and bronchial biopsy homogenates (data presented in chapter 4) 188.
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3.2.3 Inclusion criteria
i) Males and females aged 18 to 75 years inclusive.
ii) Moderate/severe asthma as defined above treated with inhaled corticosteroids, with or
without oral corticosteroids (oral up to 20mg/day prednisolone or equivalent) for at least 3
months prior to screening.
iii) Written, informed consent provided.
3.2.4 Exclusion criteria
i) Age < 18 or > 75 years.
ii) Total smoking history >10 pack years.
iii) Pregnant or lactating females or those at risk of pregnancy.
iv) Patients taking >20mg of prednisolone daily.
v) Hospitalisation for asthma or exacerbation requiring systemic corticosteroid therapy within
3 months of the screening visit.
vi) History of life-threatening asthma, defined as an asthma episode that required intubation
and/or was associated with hypercapnia, respiratory arrest and/or hypoxic seizures within the
6 months prior to screening.
vii) Pre-bronchodilator FEV1 < 40% predicted.
viii) Patients in whom omalizumab therapy was contraindicated or used only “with caution”
according to the omalizumab SmPC.
3.3 “Omalizumab in non-atopic asthma”- clinical trial overview
This was a randomised, placebo-controlled, double blind, parallel-group, proof of concept
trial of 20 weeks’ duration. Omalizumab and identical vehicle control manufactured to GCP
standards were kindly supplied by the manufacturers (Novartis Pharmaceuticals). The trial
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was approved and monitored by Guy’s Research Ethics Committee and the Medicines and
Healthcare Products Regulatory Agency.
Figure 3.1: Clinical trial flow chart outlining interventions. Baseline: Time from screening
visit to first bronchoscopy and commencement of omalizumab/placebo (Weeks -4 to 0). Time
A: Time span during which the patients had a second bronchoscopy (Weeks 12 to 14) after
which therapy was reduced. Time B: End of the trial 20 weeks from the first injection of
omalizumab/placebo.
Clinical trial design, clinical interventions, immunohistochemical and immunofluorescence
techniques are described in detail in chapter 2 (sections 2.2, 2.3, 2.4, 2.6, 2.7.1.1 and 2.7.2).
The clinical interventions are also outlined in the trial flow chart (Figure 3.1).
3.4 Statistical methods for the clinical trial
3.4.1 Powering
As explained above, in this study I elected in the first instance to provide proof of concept in a
double blind, placebo controlled study that omalizumab therapy can maintain or improve lung
function in non-atopic asthmatics despite provocation of the disease in the short term by
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supervised reduction of therapy. In a previous therapy reduction study (CQAE397A2202)
performed by Novartis using patients of similar severity and taking similar therapy at
baseline, the standard deviation of the differences in FEV1 before and after reduction of
inhaled corticosteroid was found to be 9.550. Using twenty subjects per group this would give
a 90% chance of detecting a 10% difference in changes in FEV1, with an alpha of 0.1 using a
two-sided test. Reduction in deterioration of the FEV1 following withdrawal of therapy over
the 20 weeks of the study in the omalizumab, compared with the placebo treated group was
thus set as the primary outcome measure. The immunohistochemical changes were
unprecedented and so could not be formally powered. Nevertheless, the difference between
the changes in the median numbers of bronchial mucosal IgE+ cells in the active and placebo
treated groups between baseline and time A was considered as a co-primary outcome since
such a finding would furnish proof of principle that the omalizumab therapy as delivered had
exerted tangible effects on binding of IgE to cells bearing its receptors within the target tissue.
3.4.2 Statistical analysis
Baseline characteristics and demographic data were summarised using descriptive statistics.
Changes in numerical variables at the beginning and end of the study as well as differences in
changes between the omalizumab and placebo treated groups were analysed by non-
parametric statistics (Mann-Whitney U test). All tests were two sided and p<0.05 was
accepted as significant. The statistical software package used was GraphPad Prism version 5.
3.5 Results
3.5.1 Patients
Of 30 patients screened, 18 were randomised (1:1) and 15 completed the study. The patients
randomised to omalizumab or placebo therapy were well matched in terms of distributions of
109
age, sex, body mass index, serum total IgE concentrations, blood eosinophil counts, exhaled
nitric oxide measurements, smoking history, lung function, asthma symptom scores and
inhaled corticosteroid dosages (Table 3.3). There were 5 males and 3 females in the
omalizumab group, and 3 males and 5 females in the placebo group. In the omalizumab vs.
placebo treated groups, 7 vs. 8 patients were taking long-acting 2-agonist, 4 vs. 1 were taking
oral leukotriene receptor antagonist and 2 vs. 2 were taking oral theophylline preparations.
These medications were all stopped or substituted at Time A (Figure 3.1). 3 patients each in
the omalizumab and placebo treatment groups had screening blood eosinophil counts >
0.4x109/L, suggesting an equal distribution of so-called “eosinophilic” asthma between the
groups, although this was not a selection criterion, nor was it hypothesised to influence the
primary outcome measures.
3.5.2 Steroid reduction
One patient randomised to omalizumab and 3 randomised to placebo were taking oral
prednisolone at dosages of 15 mg/day and 15, 10 and 5 mg/day respectively which were
reduced to 7.5 mg/day and 7.5, 5 and 0 mg/day respectively according to the predetermined
regimen as shown in tables 3.1 & 3.2.
Inhaled corticosteroid dosages were reduced in both groups to 400g/day beclometasone
equivalent (Symbicort 100/6 Turbohaler 2 puffs twice daily) between 12 and 16 weeks and
further to 200 g/day (Symbicort 100/6 Turbohaler 1 puff twice daily) between 16 and 20
weeks.
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Table3.1: Protocol for the reduction of prednisolone dosage
Table 3.2: Prednisolone reduction in individual patients
Randomisation
Prednisolone dose (mg)
Baseline Time A (week 12-14) Time B (week 20)
Omalizumab 15 10 7.5
Placebo i) 15 10 7.5
ii) 10 7.5 5
iii) 5 2.5 0
Starting dose of
Prednisolone (mg)
Time A (week 12-14) Week 16 Time B (20 weeks)
20 15 10 10
17.5 12.5 7.5 7.5
15 10 7.5 7.5
12.5 7.5 5 5
10 7.5 5 5
7.5 5 2.5 2.5
5 2.5 0 0
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Characteristics & Outcomes Randomisation Baseline 12 -14 weeks (Time A)(Prior to reduction of therapy) 20 weeks (Time B)
Age (yr)
Omalizumab 47 (22, 66)





Omalizumab 84 (55, 133)
Placebo 87.50 (61, 112)
Height (cm)
Omalizumab 172 (155, 178)




Serum total IgE (IU/ml)
Omalizumab 75 (8, 264)
Placebo 49 (2, 284)
Blood eosinophil count (x109/L)
Omalizumab 0.3 (0, 1)
Placebo 0.1 (0, 0.7)
FEV1 (L)
Omalizumab 2.44 (1.81, 3.43) 0.225 (-0.32, 1.24) 0.26 (0.03, 0.67) *
Placebo 2.34 (1.16, 3.66) 0.005 (-0.30, 0.45) -0.06 (-0.63, 0.39)
FEV1 % predicted Omalizumab 75 (50, 98) 6 (-13, 36) 11 (1, 19) **Placebo 80 (47, 114) -4 (-11, 14) -2 (-23, 15)
PEFR (L) Omalizumab 364 (233, 480) 10.50 (-3, 55) 17.50 (-34, 104)Placebo 308 (174, 455) 8.50 (-41, 92) 4 (-83, 111)
ACQ score Omalizumab 2.28 (1.43, 3.43) -0.50 (-1.85, 0.72) -0.71 (-1.14, 0.14)Placebo 2.42 (0.71, 3.28) -0.35 (-1.00, 0.57) -0.28 (-1.71, 1.14)
AQLQ score Omalizumab 4.33 (2.53, 5.27) 0.18 (-1.00, 2.26) 0.46 (-0.40, 2.06)Placebo 4.60 (3.73, 5.80) 0.37 (-1.34, 1.87) 0.67 (-1.60, 2.30)
ACD score Omalizumab 1.86 (0.86, 2.84) 0 (-1.15, 0.45) -0.28 (-1.21, 0.65)Placebo 1.97 (0.39, 2.80) -0.26 (-1.45, 1.10) -0.24 (-1.52, 2)
Exhaled NO (ppb) Omalizumab 26.5 (18, 95) 36 (16, 80) 31 (12, 134)Placebo 21.5 (10, 42) 19 (5, 40) 20 (8, 142)
Inhaled corticosteroid dosage (BDP equivalent:
μg/day) 
Omalizumab 2000 (800, 4000) Reduced to 400μg BDP 
equivalent/day
Reduced to 200 μg BDP 
equivalent/dayPlacebo 1800 (500, 2000)
Table 3.3: Baseline demographics and clinical characteristics of non-atopic asthmatics randomised to omalizumab or placebo therapy and absolute changes from Baseline at Times A and B (see Figure 2.1). All
variables are shown as the median and range. PEFR: Peak Expiratory Flow Rate, ACQ: Juniper Asthma Control Questionnaire, AQLQ: Juniper mini-Asthma Quality of Life Questionnaire, ACD: Asthma Control
Diary. *p = 0.04, **p = 0.015 (Mann-Whitney U Test).
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3.5.3 Adverse events and withdrawals (Figure 3.2: Consort diagram)
One patient from the placebo group withdrew after the screening visit for personal reasons.
Two patients randomised to omalizumab therapy withdrew from the study prematurely, one
following an asthma exacerbation (an expected adverse event) at week 5 and another who
elected to withdraw after 16 weeks because of subjective deterioration of symptoms not
confirmed by spirometry. There were no other adverse events.
113
Figure 3.2: Omalizumab Study CONSORT Flow Diagram
Assessed for eligibility, n= 30
Excluded, n= 12
 Not meeting inclusion criteria, n= 12
 Declined to participate, n= 0
 Other reasons, n=0
Analysed, n=7
 Excluded from analysis, n=2
i) Received only 2 doses of the intervention
ii) Could not complete the treatment reduction
phase, so excluded from the analysis of the
clinical outcomes
i) Discontinued intervention due to asthma
exacerbation week 5, n=1
ii) Discontinued intervention due to subjective
deterioration of symptoms after week 16, n=1
Allocated to Omalizumab, n=9
 Received Omalizumab, n=9
 Did not receive allocated intervention, n=0
Lost to follow-up, n=0
Discontinued intervention, n=0
Allocated to Placebo, n=9
 Received Placebo, n=8
 Did not receive allocated intervention due to
personal reasons, n=1
Analysed, n=8







3.5.4 Primary outcome measure: FEV1
Spirometry was performed at baseline and at Times A and B (Figure 3.1). Comparisons of
changes in median absolute and % predicted FEV1 from baseline to Time A (12 - 14 weeks),
and from Time A to B (12 - 20 weeks) did not show any statistically significant differences
between the omalizumab and placebo groups. However, compared with baseline, in
accordance with the planned primary outcome measure, changes in median absolute and %
predicted FEV1 by 20 weeks were positive in the omalizumab treated patients, despite
substantial reduction of existing anti-asthma treatment, but negative in the placebo treated
patients (median (SIQR) change 0.26 (0.07, 0.64) vs. -0.06 (-0.14, 0.27) litre, p=0.04; 11 (2,
18) vs. -2.0 (-11, 1.5) % predicted, p=0.015: see Figure 3.3 and Figure 3.4. (A comment from
the statistician regarding the suitability and validity of this analysis is attached in Appendix
4).
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Figure 3.3: Comparison of effect of treatment with omalizumab and placebo on changes in
absolute and % predicted FEV1 between Baseline and Times A (12 - 14 weeks) and B (20
weeks) (see Figure 2.1 for definitions). Bars represent the median and interquartile range;
Mann-Whitney U Test. Light shading: omalizumab treated patients; dark shading: placebo
treated patients.
Figure 3.4: Comparison of effect of treatment with omalizumab and placebo on absolute
FEV1 of individual patients between Baseline and Times A (12-14 weeks) and B (20 weeks)




As shown in Table 3.3, the median PEF and ACQ scores between baseline and Time B (20
weeks) improved by what is regarded as a clinically significant degree in the patients
randomised to omalizumab therapy but not placebo, although the differences between the
groups did not quite attain statistical significance in non-parametric testing. In contrast, ACD
and mini-AQLQ scores improved to a similar extent in both groups despite reduction of
conventional therapy.
3.5.6 Markers of airway inflammation
The median numbers of tryptase+ mast cells, CD20+ B cells, CD138+ plasma cells, CD38+
plasmablasts, total IgE+ cells (most of these were likely mast cells), IgE+/tryptase+ mast cells,
IgE+/CD20+ B cells, IgE+/CD138+ plasma cells, and BMK-13+ eosinophils per unit area of the
bronchial biopsy sections just prior to commencement of omalizumab and at Time A (after
12-14 weeks of omalizumab or placebo therapy with no alteration of existing medications, see
Figure 3.1) are shown in Table 3.4, while selected changes are depicted graphically in Figure
3.5 and typical examples of the immunofluorescent and immunohistochemical techniques
shown in Figure 3.6 and Figure 3.7 respectively. I observed a significant reduction in the
median total number of IgE+ cells (p<0.001), the co-primary outcome measure, in the
bronchial mucosa in the patients treated with omalizumab but not placebo. No significant
changes were observed in the median numbers of any of the other cells analysed following
omalizumab or placebo therapy. Very few of the B cells and plasma cells showed detectable
IgE immunoreactivity as expected (Table 3.4), so it was impracticable to evaluate changes.
Conglomerates of CD38+ plasmablasts and CD20+ B cells were detected in approximately 1
in every 10 sections of the mucosa (Figure 3.5F), but again these were insufficient in number








baseline and Time A (12-14




Omalizumab 7.22 (0, 124.77) 10.88 (-61.64, 57.70)
Placebo 29.92 (4.32, 75.64) 3.68 (-14.66, 13.08)
CD20+
B Cell
Omalizumab 1.48 (0.00, 9.67) 0.00 (-8.25, 4.80)
Placebo 2.10 (0.29, 9.35) -0.15 (-1.32, 6.39)
CD138+
Plasma Cell
Omalizumab 0.00 (0.00, 36.63) 0.00 (-4.42, 3.47)
Placebo 1.68 (0.00, 6.80) -0.24 (-1.93, 1.13)
CD38+
Plasmablast
Omalizumab 3.91 (0.00, 14.57) 3.07 (-3.83, 69.72)
Placebo 0.61(0.00, 39.39) -0.21 (-28.39, 8.67)
IgE+ Cell Omalizumab 12.38 (1.22, 175.90) -5.44 (-109.89, -1.30)**
Placebo 16.45 (2.86, 60.92) 4.98 (-17.08, 17.81)
IgE+ /Mast cell Omalizumab 9.19 (0.00, 124.46) -1.89 (-99.94, 33.31)
Placebo 26.16 (4.32, 50.23) 7.88 (-17.58, 24.08)
IgE+ /B cell Omalizumab 0.00 (0.00, 0.28) 0.00 (0.00, 0.32)
Placebo 0.00 (0.00, 0.00) 0.00 (0.00, 0.00)
IgE+ /Plasma
cell
Omalizumab 0.00 (0.00, 5.98) 0.00 (-5.41, 0.00)
Placebo 0.00 (0.00, 0.46) 0.00 (-0.46, 0.00)
BMK-13+
Eosinophils
Omalizumab 9.03 (2.92,17.20) -0.76 (-14.40, 4.47)
Placebo 4.26 (0.31, 21.36) 0.81 (-9.65, 7.57)
Table 3.4
Bronchial mucosal inflammatory cells: absolute counts (median, range) per mm2 at baseline
and change following treatment with omalizumab/placebo at Time A (see Figure 2.1).
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Figure 3.5
Effects of omalizumab and placebo treatment on numbers (cells/mm2) of bronchial mucosal
(A) total IgE+ cells; (B) tryptase+ mast cells; (C) IgE+/tryptase+ mast cells; (D) CD138+
plasma cells; (E) CD38+ plasmablasts. Median with interquartile range; Mann-Whitney U
Test. (F) Immunofluorescence image of a typical conglomerate of plasmablasts in the
bronchial mucosa stained with anti-CD38 (red) in a background of nucleoprotein (blue).
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Figure 3.6: Immunofluorescence image of bronchial biopsy from a non-atopic asthmatic
patient stained for plasma cells (CD138; green), IgE (red) and nucleus (blue). Top: View of
whole biopsy, showing area of magnification. Bottom: Magnified view, with a merged image
and individual stains. Arrows indicate cells with dual staining (plasma cells expressing IgE).
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Figure 3.7: Immunofluorescence & immunohistochemistry images of bronchial
biopsies from non-atopic asthma patients
Tryptase + cells (green)




This section of my PhD thesis was conceived to challenge, in the light of current knowledge,
the tacit assumption that omalizumab therapy is of no potential clinical benefit in
conventionally defined, non-atopic asthmatics. In place of a large, long-term, conventional
clinical trial in the first instance, which would have been difficult to fund due to the paucity of
supportive evidence, I wished to provide proof of concept that omalizumab therapy of these
patients exerts a favourable effect on lung function, as assessed by changes in the FEV1, and
reduces IgE expression and IgE sensitisation of target cells within the bronchial mucosa (co-
primary outcome measures) following a period of therapy with omalizumab followed later by
withdrawal of existing, conventional therapy. I first obtained bronchial biopsies before and
after 12-14 weeks of treatment of the non-atopic, asthmatic patients with omalizumab or
placebo while maintaining existing therapy in order to address the hypothesis that
omalizumab compared with placebo, under conditions where conventional asthma therapy is
maintained, reduces local IgE binding to inflammatory cells within the bronchial mucosa, the
co-primary outcome measure. To obtain proof of concept that omalizumab can improve lung
function, I then destabilised the patients by staged reduction of their therapy according to a
protocol previously validated by Novartis and powered to detect changes in FEV1, the second,
co-primary outcome measure. Although I was unable, despite my highest and most strenuous
endeavour, to recruit as many subjects as demanded by the power calculation because
recruitment to this complex and demanding study proved challenging (see further comments
below), I did nevertheless did observe a significant improvement in the median FEV1 when
compared with baseline in those patients who received omalizumab, but not placebo, over the
20 week period of the study, incorporating the therapy reduction phase on which the study
was powered and also incidentally comparable to the time frame used to gauge responsiveness
clinically. I also explored changes in quality of life and asthma symptom scores and, although
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the study was not powered to examine these it revealed a modest improvement in the ACQ,
but not the mini-AQLQ score. It is arguable that the ACQ score is more reflective of short-
term asthma stability than mini-AQLQ, which may improve in response to increased
surveillance in the context of a clinical trial. These data are congruent with a previous
placebo-controlled proof of concept clinical trial by Garcia and colleagues examining the
clinical effects of omalizumab in non-atopic asthmatics207, who were also able to demonstrate
improvement of FEV1 in their patients and a trend towards improvement in global evaluation
of clinical effectiveness and asthma exacerbation rate and another observational study using
data from Spanish multicentre registry208.
Two patients randomised to omalizumab therapy withdrew, the first following an
exacerbation just after commencing omalizumab and prior to any change in therapy. The
second patient elected to withdraw during the therapy reduction phase despite lack of any
objective evidence of deterioration (please refer the consort diagram, Figure 3.2). The data
from this patient’s bronchial biopsies, but none of the clinical data were included in the final
analysis. Although in larger studies withdrawal rates may reflect the efficacy of a novel
therapy, this is clearly not applicable in the present study. One patient assigned to
omalizumab and three to placebo were taking oral corticosteroids. Since we hypothesised that
omalizumab reduces IgE expression in the target organ of non-atopic asthmatics whose
existing therapy is maintained, and that omalizumab therapy preserves/improves FEV1 in the
face of significant therapy reduction, it is unlikely that my conclusions have been influenced
by this.
Having demonstrated that IgE is increased in the bronchial mucosa of non-atopic
asthmatics188, I here additionally show that omalizumab therapy substantially reduces the
numbers of cells (likely principally mast cells) exhibiting associated IgE, consistent with my
hypothesis (and also incidentally clearly suggesting that omalizumab penetrates the bronchial
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mucosa when administered therapeutically to these patients). This presumably reflects
sequestering by omalizumab of free IgE within the bronchial mucosa, resulting in down
regulation of its receptors on local target cells 128,209,210. Similarly, in a study of mild atopic
asthmatics185, treatment with omalizumab was associated with a reduction in the numbers of
bronchial mucosal FcRI+, IgE+ cells, eosinophils, T lymphocytes and B lymphocytes.
Returning to the question of why inhibition of binding of IgE to its receptors, which is the
only established, direct anti-inflammatory action of omalizumab may benefit asthma
regardless of conventional atopic status, it is worth examining the data from the INNOVATE
study post-hoc analysis which suggested that subgroups of the severe allergic asthmatics
participating in this study with relatively high baseline eosinophil counts derive the greatest
clinical benefit from omalizumab211. Although such post-hoc conclusions should properly be
regarded with caution, this observation is consistent with data discussed previously in the
introductory chapter suggesting that one of the principal actions of omalizumab may be to
restore asthma stability by restoring innate, anti-viral immunity. This may partly account for
the INNOVATE post-hoc analysis findings, since asthma patients who are relatively unstable
and in and out of hospital despite being on high step anti-asthma therapy are often patients
with relatively high blood eosinophil counts and frequent viral exacerbations of disease. Of
course my own study was neither intended nor powered to examine variation in
responsiveness to omalizumab according to blood eosinophil counts.
Whatever the precise anti-inflammatory actions of omalizumab, it seems clear that its clinical
effectiveness varies in individual patients in a manner not predicted by their baseline,
circulating IgE concentrations212, suggesting that responsiveness does not simply reflect
overall IgE production (at least in the circulation). In addition, Chanez and colleagues213
showed that, while in a group of severe atopic asthmatics omalizumab therapy reduced
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expression of FcRI on blood basophils and plasmacytoid dendritic cells (a finding also
confirmed in the study by Garcia and colleagues214), there was no correlation with clinical
responsiveness.
To further explore possible functional consequences of omalizumab therapy I looked for
changes in inflammatory cell numbers in the bronchial mucosa (such changes cannot prove
cause and effect but may provide mechanistic clues). In the event I observed none. One caveat
is the issue of cell clusters. It was with great interest that I noticed clusters of CD38+
plasmablasts and CD20+ B cells in approximately 1 in 10 sections of the bronchial mucosa,
consistent with the previous observations in the literature that these cells switch locally to IgE
synthesis 53: this would likely be accompanied by multiple cellular divisions215. It is
technically challenging to enumerate changes in numbers of cells distributed as discrete
clusters. Even assuming, however, that omalizumab does also inhibit local B cell
differentiation and IgE synthesis in the bronchial mucosa, consistent with its known effects on
IgE expressing B cells and antigen-presenting cells 216,217, it is again not yet absolutely clear if
and why this may be important in asthma.
3.7 Issues and shortcomings of the study
The original objective when designing this clinical trial was to recruit 40 participants in order
to be certain of having the statistical power to detect a difference in changes in FEV1 between
the omalizumab and placebo treated groups. At one stage when thinking about the design of
the original trial protocol is was mooted that asthma exacerbation rate, defined as a need for
rescue oral prednisolone treatment for deteriorating symptoms and/or lung function in the
therapy reduction phase of the study should also be examined as an outcome measure, but it
quickly became clear that, with such a short trial this was out of the question because of the
paucity of such events (in fact only one of the patients suffered a true disease exacerbation
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during the trial and this was not during the therapy reduction phase). It was also planned (and
executed) to monitor, speculatively, a full range of additional, conventional clinical outcome
measures (symptom scores, QoL scores and FeNO). Powering is designed principally to
eliminate the possibility of Type 2 error, which refers to the situation when a significant
difference between two sets of variables is obscured by the inherent variation of the variables
being measured. Fortunately, in this study a statistically significant difference between the
groups was indeed observed in the primary outcome measure variable (FEV1) despite under
recruitment (<50% of the intended sample size), which by definition obviates Type 2 error. I
should add that I did everything in my power to attain this recruitment target. The main
difficulty encountered during recruitment was identifying sufficient numbers of eligible,
moderate/severe non-atopic asthmatic patients satisfying all of the inclusion & exclusion
criteria. Many non-atopic asthmatics failed screening based on their failure to meet the (ad
hoc but conventional) spirometric criteria used to define asthma, their smoking status
(although I felt obliged to accept ex-smokers who met the inclusion criteria) and the time
interval from a previous exacerbation. Many otherwise likely eligible candidates were
unwilling to consider participation because of the time commitment involved, the necessity
for time off work and the prospect of undergoing two successive bronchoscopies with
bronchial biopsy. Finally, I believe it is fair to state that the assistance I anticipated with
recruitment of suitable patients from the other two centres was far from as extensive as I had
hoped (in fact I personally recruited all but two of the patients in this study).
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Chapter 4: Total and allergen-specific IgE in the bronchial




IgE binds to its high affinity receptor FcRI on mast cells in the target organs of allergy in
surveillance for antigen. The cognate interaction of a multivalent antigen cross-links the
receptors to induce mast cell activation. Activated mast cells release mediators of the
immediate reaction to the antigen (allergen) and initiate an inflammatory cascade: allergic
inflammation. This in turn may result in exacerbation (some speculate causation) of asthma,
although in many patients with peripheral, allergen-specific IgE allergen exposure has no
obvious clinical sequelae. A similar clinical syndrome is manifest in “non-atopic” asthma, in
the apparent absence of provoking allergens, as typically deduced from negative skin prick
tests with a panel of common allergens or the absence of detectable allergen-specific IgE in
serum. Thus, the propensity for allergen or indeed IgE to provoke non-atopic asthma is
unclear. We have shown, however in previous studies119,123,202 that the entire molecular
machinery to support local B cell IgE switching is in place in the bronchial mucosa of non-
atopic, as well as atopic asthmatics and that switching does indeed occur at this site126,218.
Finally, local expression of FcεRI on inflammatory cells is elevated to an equivalent degree in 
the bronchial mucosa of non-atopic, as well as atopic asthmatics39, which is also consistent
with local IgE concentrations in excess of those in the serum of these patients since IgE up
regulates expression of its own high-affinity receptor219. Furthermore, epidemiologically,
elevated IgE production is a significant risk factor for asthma regardless of its
specificity125,220.
One possible explanation for this paradox is that aeroallergens may provoke a local, specific
IgE response in non-atopic asthmatics in the bronchial mucosa but that this IgE is captured by
local mast cells in the tissue and does not reach peripheral mast cells in the skin or the
circulation. There is some precedent for this in non-atopic rhinitis90 .
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To begin to solve this paradox in the present study, I first sought to determine whether some
of the patients classified as non-atopic asthmatics had IgE antibodies against known allergens,
but that these IgEs were confined to the bronchial mucosa. This was an obvious possibility
given preliminary similar findings in non-atopic rhinitis90 and the continuity of the
respiratory tract mucosa from the nose to the lung.
Accordingly, I compared the concentrations and specificities of the IgE in the blood and
bronchial mucosa of atopic and non-atopic asthmatics and non-atopic controls. I hypothesised
that local IgE synthesis in the bronchial mucosa of both atopic and non-atopic asthmatics
results in greater local total IgE concentrations than in the serum and, in the case of non-
atopic asthmatics, production of allergen-specific IgE which is sequestered in the mucosa and
therefore not detectable in the periphery. I tested the specificities of IgEs in both
compartments, not only to the panel of allergens originally used in the skin prick tests, but
also to a panel of over 100 known allergen components, to investigate the further possibility
that the IgEs may be specific for uncommon allergens.
4.2 Materials and methods
A total of 10 each of atopic & non-atopic asthmatics and non-atopic non-asthmatic controls
were recruited and bronchial mucosal biopsies and blood samples collected as described in
Chapter 2: sections 2.1, 2.2, 2.3, 2.5 and 2.6. Further sample processing, protein extraction
methods and IgE assay (ImmunoCAP and ISAC) are described in detail in Chapter 2: sections
2.7.1.1, 2.7.1.3 and 2.7.3
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4.3 Statistical analysis
Statistical analysis was performed using Kruskal-Wallis ANOVA & Dunn’s multiple
comparisons test. The statistical software used was GraphPad Prism, version 5.
4.4 Results
Relevant clinical and demographic details of the subjects are summarised in Tables 4.1 and
4.2. The median ages of the atopic and non-atopic asthmatics were not statistically different
although significantly higher in both groups than those of the controls. The median FEV1 of
the non-atopic asthmatics was significantly lower than that of the atopic asthmatics and the
controls, while the median FEV1 of the milder atopic asthmatics and controls did not
significantly differ. The non-atopic asthmatics were taking a significantly elevated median
daily dosage of inhaled corticosteroid compared with the atopic asthmatics, in accordance
with their more severe disease.
4.5 Total IgE in bronchial biopsies and serum
IgE was detectable in the serum and bronchial mucosa of all of the atopic and non-atopic
asthmatics and non-atopic controls (Figure 4.1). The median serum total IgE concentration
was significantly elevated in the atopic (p = 0.001), but not the non-atopic (p = 0.32)
asthmatics as compared with the non-atopic controls (Figure 4.2). In contrast, the median total
IgE concentration in the bronchial mucosal homogenates was significantly elevated in both
the non-atopic (p = 0.003) and the atopic asthmatics (p = 0.038) compared with the controls.
These differences remained statistically significant even after allowing for variability of IgE
concentrations between different mucosal sites as described below. Comparing the atopic and
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non-atopic asthmatics, there was no significant difference in the median total IgE
concentrations either in the mucosa (p > 0.99) or in the serum (p = 0.14).
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Subject group Non-atopic controls Non-atopic asthmatics Atopic asthmatics
Age (yr) 23 (21-36) 54 (24 - 70) * 30.50 (24-66) *
Sex (F/M) 3/7 4/6 4/6
FEV1
(% predicted)
104.5 (94-128) 67.5 (40-101) ** 95 (64-130) #
Blood eosinophil count (x 109/L) 0.1 (0-0.4) 0.25 (0-0.7) 0.35 (0.1-1.1) *
Inhaled corticosteroid dosage (µg/day BDP equivalent) 1800 (640-4000) 150 (0-1600) ##
Table 4.1: Demographics & lung function of study subjects and corticosteroid therapy of asthmatics. Age, FEV1 % predicted, blood eosinophil
count at recruitment and inhaled corticosteroid dosages are expressed as the median (range). 3 non-atopic asthmatics were taking regular oral
prednisolone in addition to inhaled corticosteroids. (F: Female; M: Male; BDP: Beclometasone dipropionate). *p0.01; **p0.005 vs. controls;
#p=0.02; ##p=0.002 vs. non-atopic asthmatics (Kruskal-Wallis ANOVA & Dunn’s multiple comparisons test).
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No. Age Sex Positive sensitisation status
1 24 F Cat, Dog
2 29 M Grass, Tree, Cat, Dog, HDM, Mould
3 66 F Grass, Cat, Dog, HDM, Mould
4 32 F Grass, Cat, HDM, Mould
5 28 M Grass, Tree, Cat, Dog, HDM, Mould
6 54 M Tree, Cat, Dog, HDM, Mould
7 24 F HDM
8 26 M Grass, Cat, HDM
9 47 M Mould
10 35 M Tree, Grass, HDM, Mould, Cat, Dog




Total IgE concentrations in the serum (left Y axes, open bars) and the bronchial mucosa (right




Box and whisker plots summarising total IgE concentrations in the serum (left) and bronchial
mucosa (right) of the non-atopic controls (NAC), atopic asthmatics (AA) and non-atopic






























Concentrations of IgE specific for a range of common and some uncommon allergen
components were measured using ImmunoCAP ISAC microarray in the three subject groups.
Allergen component-specific IgE species were detectable in the sera and biopsy homogenates
of the atopic asthmatics. The relative concentrations of a minority of these components,
expressed as percentages of the total IgE, were higher in the mucosa than in the serum.
Figures 4.3, 4.4 & 4.5 and tables 4.3, 4.4 & 4.5 show only positive data obtained from the
standard ISAC assay. In some of the atopic subjects sensitised to particular allergens by
conventional criteria (SPT or PhadiaCAP), IgE against none of the corresponding allergen
components in the standard ISAC chip was detectable in the serum or the bronchial mucosa
(subjects sensitised to - grass: 3, 4 and 8; tree: 2; moulds: 3, 4, 5 and 6; cat: 4; dog: 3).
Component specific IgE concentrations did not exceed the threshold of detection of the ISAC
assay in the sera and mucosa of the non-atopic asthmatics or controls, in agreement with their
negative skin prick and PhadiaCAP test results.
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Figure 4.3
Concentrations of IgE specific for grass (Phl p 1, Phl p 2, Phl p 4, Phl p 5, Phl p 6, Phl p 11
and Cyn d 1) and tree (Bet v 1, Ole e 1, Cry j 1, Cup a 1 and Pla a 2) allergen components are
expressed as percentages of the total IgE in the sera (open bars) and the bronchial mucosa
(filled bars) of atopic asthmatics. Subjects sensitised to the corresponding allergens by
SPT/ImmunoCAP are indicated by arrowheads.
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Figure 4.4
Concentrations of IgE specific for HDM (Der p 1, Der p 2, Der f 1, Der f 2 and Eur m 2) and
mould (Asp f 1, Asp f 3, Asp f 6 and Alt a 1) allergen components are expressed as
percentages of the total IgE in the sera (open bars) and the bronchial mucosa (filled bars) of




Concentrations of IgE specific for cat (Fel d 1, Fel d 2 and Fel d 4), and dog (Can f 1, Can f 2
and Can f 3) allergen components are expressed as percentages of the total IgE in the sera
(open bars) and the bronchial mucosa (filled bars) of atopic asthmatics. Subjects sensitised to
the corresponding allergens by SPT/ImmunoCAP are indicated by arrowheads.
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Table 4.3: Allergen component (Grass and Tree) specific IgE concentrations from the serum (ng/ml) and bronchial mucosa (ng/g) of atopic























































5 Mucosa 6.00 29.04
Serum 121.00 84.70 3.63 70.18 53.24 3.63 79.86 75.02 1.21 9.44 94.38 2.90









Serum 106.48 11.37 15.25 1.45
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Der p 1 Der p 2 Der f 1 Der f 2 Eur m 2 Lep d 2 Blo t
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Serum 31.46 157.30 12.83 125.84 104.06
3
Mucosa
Serum 3.87 24.20 2.90 19.84 18.15
4
Mucosa 13.83 10.37 8.64






Serum 0.97 3.15 0.97 2.66 2.42
7
Mucosa 43.56 188.76 196.02
Serum 1.45 3.87 2.42 10.65
8
Mucosa 36.30 29.04 29.04 0.97 29.04






Serum 20.57 193.60 38.72 242.00 29.04
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ng/ml ng/g ng/ml ng/ml ng/g ng/ml ng/ml ng/ml ng/ml ng/ml ng/ml
1 Mucosa 19.36
Serum 6.78 21.30 2.18
2 Mucosa



















A maximum of approximately 50% of the total IgE originally present in the mucosal
biopsies was lost during extraction. The most significant loss (approximately 40%) was
following concentration of the homogenates using the Vivaspin2 spin columns, and then
during detergent (CHAPS) removal (approximately 10%). This latter step was deemed
necessary since CHAPS inhibited specific IgE detection by ISAC.
4.8 Variability between biopsies
IgE concentrations between multiple (n=10) biopsies from a single atopic asthmatic
subject varied by a maximum of approximately two fold (median 1180 ng/g tissue, range
837 - 2531, interquartile range 783) (Table: 4.6).
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Table 4.6: Component specific IgEs detected by ISAC technique from serum and 9 different bronchial mucosal sites of an atopic asthmatic
subject. Results are expressed in ISAC standardised units (ISU)
Component specific IgEs
Grass Tree Cat Mould HDM












Serum 6.3 44 4.7 0.6 7.4 3.8 12 16 >100 8.5 80
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4.9 Discussion
So far as I am aware this is the first study in which total and allergen-specific IgE
concentrations in the bronchial mucosa of asthmatics, both atopic and non-atopic, have
been measured successfully. Arguably this is a more meaningful site at which to measure
it since presumably mucosal IgE at least initiates IgE-mediated reactions to allergens.
As expected, I observed a significantly elevated median total serum IgE concentration in
the atopic asthmatics as compared with the non-atopic controls. In the non-atopic
asthmatics, the median serum IgE concentration was also elevated, albeit not
significantly. This is consistent with previous studies showing elevated serum total IgE
concentrations compared with controls in non-atopic asthmatics113 and epidemiological
studies125,220 demonstrating that elevated serum IgE concentration is a risk factor for
asthma regardless of its specificity. The measurements of total IgE in the bronchial
mucosa of non-atopic asthmatics are entirely novel and demonstrate a median total IgE
concentration in this compartment at least comparable with that in atopic asthmatics and
clearly elevated compared with control subjects. These observations support the
hypothesis that local IgE synthesis or at least sequestration is ongoing in this
compartment in both atopic and non-atopic asthmatics.
When expressing total IgE “concentrations” in the bronchial mucosa I chose to express
these per unit weight of wet tissue, reasoning that water with a density of approximately
1 g/cm3 accounts for the bulk of the intracellular and extracellular content of the biopsies.
Direct comparison of IgE “concentrations” in two structurally and physiologically
distinct compartments such as the peripheral blood and the bronchial mucosa within
individuals may not of course be appropriate and I did not attempt this.
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I was able to apply the ISAC technique successfully to measure allergen-specific IgE in
the bronchial biopsies and serum from the same patients. The aim was to understand the
range of specificities of the IgE in the bronchial mucosa and serum of both atopic and
non-atopic asthmatics, with the rationale that if allergen-specific IgE is produced in the
bronchial mucosa and then partially or completely sequestered in the tissue, then the total
concentrations and the range of such specificities might be higher and broader in the
mucosa than in the serum. What was found, however was that for a range of common
local aeroallergens (house dust mite, grass, tree, moulds, cat epithelium and dog
epithelium), while most of the atopic asthmatics sensitised by conventional skin prick
testing and/or PhadiaCAP to these allergens had detectable concentrations of at least
some components of these allergens in the serum, IgE against a much smaller range of
the components was detectable in the bronchial mucosa. Furthermore, and
notwithstanding reservations about direct comparisons of the “concentrations” of IgE in
these two distinct compartments, there was little evidence that local mucosal IgE
concentrations were markedly elevated in comparison with concentrations in the serum.
The fact that some atopic subjects sensitised by conventional skin prick test and/or Phadia
CAP to grass pollen, tree pollen, moulds, cat and dog did not have detectable IgE in the
serum or bronchial mucosa to any of the ISAC chip components suggests that the
repertoire of IgE against allergen components detected by the ISAC chip is narrower than
that produced by patients, or that the threshold of sensitivity of the assay for IgE against
different allergen components is variable or both. It is also possible, however, that the
range of specificities in a single bronchial biopsy may be unrepresentative of the full IgE
repertoire in the bronchial mucosa, even though site to site differences in the total IgE
concentrations were minimal. Regional differences may reflect the clonal proliferation of
allergen-specific B cells at different sites. Another consideration is that local IgE
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production against seasonal allergens might conceivably vary seasonally. This was not
accounted for in the study. When making these comparisons I elected to express
component-specific IgE concentrations as percentages of the total IgE detected in the sera
or bronchial biopsies. Although there is considerable evidence that total and allergen-
specific IgE production are regulated independently220, it was felt that expression of data
in this way would best obviate possible variation relating to the cellular content of
individual biopsies (since IgE in the tissues is likely to be bound almost exclusively to
cells) as well as any possible losses during extraction.
Using the ISAC chip, which is clearly capable of detecting IgE against components of
common aeroallergens in the bronchial biopsies, I failed to detect specific IgE against any
allergen component in both the sera and the bronchial biopsies of the non-atopic patients,
whether asthmatic or not. These data do not therefore support the hypothesis that
allergen-specific IgE is sequestered in the bronchial mucosa of non-atopic asthmatics but
fails to appear in the circulation. Rather, they suggest that elevated local bronchial
mucosal IgE production in non-atopic asthmatics, for which we have produced abundant
indirect evidence in previous studies39,126,218, is directed against targets other than
allergens.
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Chapter 5: Anti-IgE autoantibodies and their possible effects
on the biological functions of IgE in vivo
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5.1 Introduction
In the original studies described thus far in this work I have shown that disengagement of
the IgE molecule from its receptors using anti-IgE has the propensity to improve lung
function in asthmatics not regarded as “atopic” by conventional criteria and whose
basophils and mast cells consequently apparently lack the ability to mediate Type I
hypersensitivity reactions221 following cross-linking of surface IgE-FcεRI complexes by 
conventional, multivalent allergens, resulting in activation/degranulation222 and
potentially aggravating clinical symptoms.
Aside from the possibility that non-atopic asthmatics may produce IgE responses to
exogenous, multivalent proteins not conventionally regarded as “allergens”, another
scenario that may at least partly account for the clinical efficacy of anti-IgE therapy in
non-atopic asthma is that mast cells and basophils may in some individuals be activated
by cross-linking of bound surface IgE by endogenous autoantibodies. Previous studies in
humans have suggested that some individuals spontaneously produce autoantibodies of
the IgG or IgM class which can bind specifically either to IgE or to FcεRI. Furthermore, 
some of these autoantibodies have been demonstrated to be capable of activating
basophils and mast cells independently of antigens223, as demonstrated by a variety of in
vivo and ex vivo functional assays such as autologous serum, skin prick tests224, basophil
histamine release144 and, more recently, basophil activation assays using flow
cytometry225. Most IgE-specific IgG autoantibodies have been reported to be of the IgG1
or IgG4 isotype226 and appear to recognise epitopes within the IgE Cε2 and Cε4 
domains227. In contrast, FcεRI-specific IgG autoantibodies of the IgG1 or IgG3 isotype
have been described predominantly in some patients with chronic spontaneous urticaria,
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while autoantibodies of other isotypes such as IgG2 and IgG4 have been described in
association with other autoimmune diseases such as lupus228. Autoantibodies against IgE
or FcεRI have been detected in various diseases not generally regarded as “autoimmune”, 
including atopic dermatitis229,230, asthma231 and others228,232.
Interestingly, not all of these autoantibodies show potential pro-inflammatory
activity233,234, at least as detected by the aforementioned assays so that, as with IgE itself
their activities do not reflect their local concentrations235. Furthermore, IgE-specific and
FcεRI-specific autoantibodies are also detectable in apparently healthy individuals236,237,
raising the possibility that they may in some situations actually act in an anti-
inflammatory or regulatory capacity. The prior existence in some patients of
autoantibodies with these properties may also at least partially explain why exogenous
anti-IgE therapy exerts only a marginal additional clinical benefit.
In order to investigate these possibilities further I set out to address the hypothesis that
some non-atopic asthmatic patients produce anti-IgE autoantibodies which have the
propensity to activate or inhibit target cells in an allergen-independent fashion. For the
purposes of practicability and convenience, blood basophils from these patients were
chosen as target cells, and the experiments were designed to compare responses in both
atopic and non-atopic asthmatic patients as well as non-atopic controls.
I undertook this work in discussion and collaboration with a number of colleague
laboratory scientists who helped develop, in many cases de novo, the protocols of the in
vitro experiments. I supplied the serum samples from the patients whom I had
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characterised and also participated in the performing of the laboratory work and
discussion of the data analysis. What we achieved was:
1. Development and calibration of an in vitro assay to detect and quantify IgG anti-
IgE autoantibodies in the serum samples from the patients and normal volunteers;
2. Assessment of the capacity of these sera to activate or inhibit IgE-sensitised
blood basophils from a single atopic donor in the presence and absence of
allergen;
3. Assessment of the capacity of these sera to inhibit the binding of IgE-sensitised
basophils to specific allergen using a rat basophilic cell line stably expressing
human FcRI bound to in-house manufactured monoclonal IgE directed against
the Phl p7 component of Timothy grass allergen194.
5.2 Participants and clinical interventions
17 atopic asthmatics, 19 non-atopic asthmatics and 14 non-atopic non-asthmatic control
subjects (non-atopic controls) were recruited based on the definitions and criteria
described in chapter 2, under sections 2.1, 2.2, 2.3, 2.5 and 2.6 (2.6.1, 2.6.2 & 2.6.3).
2.7.1.2, 2.7.1.3 and 2.7.4 (2.7.4.1, 2.7.4.2, 2.7.4.3, 2.7.4.4 & 2.7.4.5). Their
demographics, baseline characteristics and spirometric data are summarised in Table 5.1.
A majority of the non-atopic asthmatics (17/19; all except subjects NAA 18 & 19) were
also participants in the omalizumab study described in Chapter 3. Their serum samples




Subject group (n) Non-atopic Controls (14) Non-atopic Asthmatics (19) Atopic Asthmatics (17)
Age (yr) 24 (21-36) 49 (21-70) 31 (24-66)




0.1 (0-0.4) 0.2 (0-1) 0.3 (0.1-1.1)
FEV1 (% predicted) 106 (94-128) 73 (40-119) 96 (54-119)
Table 5.1: Demographics, baseline characteristics and lung function (FEV1%) of the
study subjects. Age, peripheral blood eosinophil count and FEV1% predicted are
expressed as the median (range)
5.2.2 Anti-IgE autoantibody experiments
The collection of peripheral venous blood, separation of sera and the isolation of PBMC
are described in chapter 2 under sections 2.5, 2.7.1.2 and 2.7.1.3. ELISA, Basophil
Activation Test and Flow cytometry were conducted as described under section 2.7.4
(2.7.4.1, 2.7.4.2, 2.7.4.3, 2.7.4.4 and 2.7.4.5).
5.3 Statistical analysis
Statistical analysis was performed using Two-Way ANOVA with Bonferroni correction
or as otherwise stated. A p value of < 0.05 was considered significant.
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5.4 Results
5.4.1 Identification of IgG class autoantibodies against free and FcεRI-bound IgE
An in-house, custom ELISA developed by my colleague Dr Chan was used to screen for
IgG class, anti-IgE antibodies in the serum samples as described in the common methods
chapter, sections 2.7.4 and 2.7.4.1. All subjects in all three groups had detectable IgG
anti-IgE autoantibodies in their sera at concentrations in excess of the threshold of
sensitivity of the assay after allowing for non-specific binding, and ranging from 22-223
ng/mL, 11-1761 ng/mL and 39-1070 ng/mL in the non-atopic controls (NAC), non-atopic
asthmatics (NAA) and atopic asthmatics (AA) respectively (Figure 5.1A).
Overall, the median concentrations of the IgG anti-IgE autoantibodies in the atopic and
non-atopic asthmatics were higher than that observed in the control subjects, achieving
statistical significance in the non-atopic, but not the atopic patients (Figure 5.1B). Of
course, the pathophysiological significance, if any, of these findings is at present
uncertain since all of the healthy controls had detectable autoantibody, so that a “normal”
range for these measurements has yet to be defined. Concentrations of IgG anti-IgE were
in excess of the 95% confidence limit of the measurements in the normal controls in the
serum samples from some of the asthmatic subjects (Figure 5.1A). Although the numbers
of these patients were relatively small, the median blood eosinophil counts and lung
function (FEV1% predicted) of the asthmatic patients (both atopic and non-atopic) with
circulating concentrations of anti-IgE autoantibodies in excess of the 95% confidence
limit of the range seen in the non-asthmatic controls were not significantly different from
those with lower concentrations within each group (Figure 5.2, Table 5.2). Taking the
study subjects as a whole, no correlation was observed between the concentrations of IgG
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anti-IgE antibodies and those of total IgE or anti-nuclear autoantibodies (Figures 5.7 &
5.8).
An interesting property of the IgE-specific autoantibodies was that they appeared to bind
equivalently to immobilised, free IgE and FcεRI-bound IgE (Figure 5.3) (with the proviso 
that FcεRI-bound IgE binding was below the limit of detection of the assay in two serum 
samples from the non-atopic asthmatics NAA9 and NAA17).
In order to calibrate the standard concentration curve for the IgG anti-IgE antibodies, we
used known concentrations of omalizumab, which is of course a synthetic IgG anti-IgE
antibody, as a standard for the IgE-binding antibodies (Figure 5.4). Since omalizumab
does not bind to FcRI-bound IgE, we utilised purified, IgG anti-IgE autoantibody from a
single patient’s serum as a standard to calibrate the ELISA for measuring FcεRI-bound 
IgE (Figure 5.5). We excluded the possibility of IgE contaminating these samples
following our purification procedure by gel electrophoresis (Figure 5.6).
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Figure 5.1A: Concentrations of IgG anti-IgE autoantibodies in sera from non-atopic
controls (NAC), non-atopic asthmatics (NAA) and atopic asthmatics (AA). Dotted line
shows 95% confidence limit of the range in controls. Bars represent the mean/SD of at
least three independent experiments.
Figure 5.1B: Comparison of IgG anti-IgE autoantibodies in sera from non-atopic
controls (NAC), non-atopic asthmatics (NAA) and atopic asthmatics (AA). Bars
represent mean and SD.
























































Table 5.2: Some baseline characteristics of the subjects with anti-IgE autoantibodies in
excess of the 95% confidence limit of the range in controls.
Figure 5.2: Comparison of baseline clinical characteristics (blood eosinophil counts and
FEV1% predicted) between the study groups (NAC: non-atopic controls; AA & NAA
Ab+: atopic asthmatics and non-atopic asthmatics with anti-IgE autoantibody
concentrations in excess of the 95% confidence limits of those observed in the NAC; AA
& NAA Ab- : atopic asthmatics and non-atopic asthmatics with anti-IgE autoantibody





































































Figure 5.3: The capacity of IgE-specific IgG autoantibodies to bind to “free” IgE (dark
bars) and FcεRI-bound IgE (grey bars). NAA 9&17 analytes below detection limit of 
assay. Bars show mean/SD of three experiments using duplicate samples.
Figure 5.4: Representative standard concentration curve for the IgG anti-IgE ELISA
using omalizumab































Figure 5.5: Representative standard concentration curve for the IgG anti-FcεRI-bound 
ELISA using anti-IgE purified from a single human serum sample.
Figure 5.6: SDS-PAGE showing the purified IgG anti-IgE from serum compared with
recombinant IgE and IgG.

















Figure 5.7: Comparison of serum total IgE and IgG anti-IgE autoantibody concentrations
in all study subjects. Spearman r = 0.08578, p>0.5.
Figure 5.8: Comparison of serum concentrations of IgG anti-IgE antibodies with anti-
nuclear autoantibodies (ANA) in all study subjects. Dotted line shows the threshold for a
positive ANA result. Spearman r = -0.02621, p>0.5.






































5.4.2 Basophil activation by sera containing IgG anti-IgE autoantibodies
A conventional, flow cytometric basophil activation assay was used to test the ability of
sera containing IgG anti-IgE specific autoantibodies to activate blood basophils isolated
from a single atopic donor in an attempt to create some uniformity in the properties of the
responder basophils (at least in the sense that they were derived from the same donor). In
order to establish a positive control we incubated these donor basophils with polyclonal,
exogenous IgG anti-IgE at a range of concentrations covering that observed in the sera of
the study subjects. As expected, this resulted in concentration-dependent activation of the
donor basophils as assessed by elevated expression of the surface activation marker
CD63 (from 3.15% to 85.6%; Figures 5.9 and 5.10). Having established this standard
curve, the same donor basophils were incubated under identical conditions with serum
samples from the study subjects. We defined basophil “activation” in this situation as
>2.67% CD63+ cells, equivalent to 3 standard deviations above the mean percentage of
basophils expressing CD63 following incubation with the donor’s own serum under
identical conditions. Using these criteria, five of the serum samples from the study
subjects were able to activate basophils, interestingly from both the non-atopic (NAA7,
NAA18) and the atopic asthmatics (AA5, AA8, AA14) (Figure 5.11). Not all of the
basophil-activating sera contained particularly high concentrations of IgG anti-IgE
(Figure 5.1A: AA8) and, conversely, not all of the serum samples with particularly
elevated IgG anti-IgE concentrations activated basophils (Figure 5.1A: NAA2, NAA16,
AA12): in other words, the ability of these sera to activate basophils did not equate with
their absolute IgG anti-IgE autoantibody concentrations.
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Figure 5.9: Response of blood basophils to polyclonal anti-IgE in vitro.
Figure 5.10: Gating strategy to determine basophil activation by flow cytometry,
comparing unstimulated and anti-IgE-stimulated PBMC.
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Figure 5.11: Basophil activating activity of sera. Dotted line shows detection threshold.
Points with error bars represent the mean/SD of at least three independent experiments.


















5.4.3 Modification of allergen-induced basophil activation by IgG anti-IgE
autoantibodies
We were finally interested to examine the ability of the sera from our study subjects
containing IgG anti-IgE autoantibodies to modify conventional, allergen-induced
basophil activation in a suitably sensitised, atopic subject. For this purpose we used blood
basophils from a single atopic donor sensitised to a major allergen of house dust mite
(Der p2). As anticipated, incubation of this donor’s blood basophils in the presence of
donor serum with Der p2 induced concentration-dependent activation (Figure 5.12).
When pre-incubated with the same donor basophils under identical conditions, none of
the five basophil-activating sera identified in the previous section significantly altered the
degree of basophil activation induced by a concentration of Der p2 optimal for this donor
(Figure 5.13) as well as a range of higher and lower concentrations of the allergen (Figure
5.14: serum from subject AA14 could not be analysed further because of the paucity of
the sample). Fascinatingly, though, we did observe significant inhibition of allergen-
induced basophil activation in the presence of sera from two other study subjects
(NAA16 and AA12) which in isolation did not directly increase basophil activation,
while serum from a third subject (NAA2) exhibited a similar inhibitory effect of
borderline significance (Figures 5.14 and 5.15).
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Figure 5.12: Concentration/response curve of blood basophils from a Der p2-sensitised
atopic donor to Der p2 allergen in vitro.
Figure 5.13: Response of the same basophils to Der p2 30 ng/mL pre-incubated with all
sera from Figure 5.1 normalised to baseline (pre-incubation of the cells with the donor’s
own serum). Bars represent the mean/SD of at least three independent experiments.
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Figure 5.14: Response of blood basophils stimulated with Der p2 (3-300 ng/mL), pre-
incubated with four sera containing IgG anti-IgE autoantibodies and basophil activating
activity.
Figure 5.15: Response of blood basophils stimulated with Der p2 (3-300 ng/mL), pre-
incubated with three sera containing IgG anti-IgE autoantibodies without basophil
activating activity normalised to baseline (pre-incubation of the cells with the donor’s
own serum).
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5.4.4 Depletion of total IgG and IgE-binding proteins from inhibitory sera abolished
inhibition of allergen-induced basophil activation
As a further confirmation of the identities of the inhibitory species identified in the
preceding section, we depleted either total IgG (Figure 5.16A) or total IgE-binding
proteins (Figure 5.16B) from the sera of subjects NAA16 and AA12 and then repeated
the experiments to examine their effects on allergen-induced basophil activation. Both of
these manipulations abolished the ability of the sera to inhibit allergen-induced basophil
activation, whereas purified IgE binding proteins, when depleted, retained this activity in
full (Figures 5.16C and 5.16D). Similar extracts from the non-inhibitory serum NAA7
showed no significant effects on allergen-induced basophil activation (Figure 5.17)
which, in acting as a negative control, demonstrated that depletion of IgG or isolation of
IgE-binding proteins did not generate basophil-modifying activity per se.
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Figure 5.16: (A) Total IgG concentrations in two test sera ex vivo and following protein
G depletion. (B) IgE-binding proteins ex vivo and following depletion and isolation of
IgE binding proteins. Effects of sera ex vivo and following (C) IgG depletion and (D)
removal and purification of IgE binding proteins on Der p2 (30 ng/mL)-induced basophil
activation normalised to baseline (using the donor’s own serum). Bars represent the
mean/SD of three independent experiments.
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Figure 5.17: Effects of the serum from NAA7 (non-inhibitory) on Der p2 (30 ng/mL)-
induced basophil activation before and after removal and purification of IgE binding
proteins. (Mean/SD of three independent experiments).
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5.4.5 Allergen binding to IgE is inhibited by IgG anti-IgE antibody containing sera
We then wished to investigate possible mechanisms of inhibition of allergen-induced
basophil activation by the inhibitory sera NAA16 and AA12. To achieve this we took
advantage of an in house system employing the rat basophilic cell line RBL-SX38, which
expresses surface human FcεRI, and recombinant IgE specific for the Timothy grass 
allergen Phl p7. First, we confirmed using flow cytometry that the recombinant IgE anti-
Phl p7 binds to the FcεRI expressed on the surface of the RBL-SX38 cells (Figure 
5.18A). Then we showed that subsequent addition of fluorochrome-tagged, recombinant
Phl p7 to the IgE-coated cells resulted in its binding to this specific antibody (Figure
5.18B). Pre-incubation of the IgE-bound RBL-SX38 cells with four of the sera which
activated basophils directly ex vivo but which did not modify allergen-induced basophil
activation ex vivo (NAA7, NAA18, AA5 and AA8, Figure 5.12: we were unable to re-test
serum AA14 owing to paucity of sample), or one serum sample from a donor in each
group selected to contain anti-IgE at the threshold of the mean concentration observed in
the controls with no basophil activating activity (NAC5, NAA11, AA9) prior to the
addition of Phl p7 did not significantly alter surface IgE or Phl p7 binding (Figures
5.18C, 5.18D). In contrast, two of the sera which inhibited allergen-induced basophil
activation ex vivo (NAA16 and AA12, Figure 5.15) significantly reduced binding of




(A) Binding of recombinant Phl p7-specific IgE to FcRI on RBL-SX38 cells. (B) Phl p7
binding following further incubation with specific allergen (representative of three
independent experiments). Changes in (C) surface bound IgE and (D) surface bound Phl
p7 on RBL-SX38 cells pre-incubated with recombinant, anti-Phl p7 IgE, test sera then




Using the experiments described in this chapter, which were conceived and carried out
entirely in house, we were able to develop an entirely new technique for the quantitation
of serum IgG anti-IgE autoantibodies. Previously these have been identified only
indirectly using histamine release assays143, or as arbitrary optical density readings in
uncalibrated ELISA226,238. We succeeded in calibrating our assay using known
concentrations of omalizumab, a monoclonal IgG anti-IgE antibody, recombinant IgE as
the capture antigen and a pan-anti-human IgG polyclonal antibody for detection.
Using this assay we have been able to show that, in a subset of asthmatics, and regardless
of their conventional atopic status, it is possible to detect circulating IgG anti-IgE
autoantibodies in excess of the range observed in a group of non-diseased, control
subjects. Although this was arguably a sporadic finding, and accepting that its
“pathological” significance cannot be clearly gauged from our experiments since the
“normal” range was derived from a limited group of subjects, we nevertheless feel that
these observations are of great potential interest from the point of view of a possible role
for IgE-mediated mechanisms in asthma, since my additional, personal data from chapter
4 (published) clearly suggest that IgE is expressed to excess in the bronchial mucosa of
asthmatics regardless of conventional atopic status188,239, so that the additional presence
of systemic IgG anti-IgE autoantibodies capable of directly activating cells bearing
sufficient surface-bound IgE240 could represent a mechanism for local, allergen-
independent disease exacerbation. Equally significantly, however, the data also show
that some IgG anti-IgE autoantibodies have the potential actually to inhibit allergen-
induced activation of basophils expressing surface allergen-specific IgE, at least partly by
inhibiting the binding of this IgE to allergen. This may partly explain why, in this and
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previous studies, measured concentrations of these antibodies correlate poorly with their
clinical effects241,242, and also why they do not necessarily cause disease241. More
fundamentally, though, they may at least partly explain phenomena such as why some
atopic subjects who manufacture allergen-specific IgE do not develop allergic disease,
and why in some patients with asthma, who may manufacture IgE inhibitory IgG
endogenously, exogenously administered IgG anti-IgE therapy, such as with omalizumab,
proffers little additional clinical benefit.
These studies do not of course address regulatory mechanisms of IgG anti-IgE
autoantibody production in individual subjects. We observed no correlation between the
production of these antibodies and the production of other potentially pathogenic IgG
autoantibodies such as anti-nuclear autoantibodies (Figure 5.8). Similarly, and in contrast
to certain earlier studies231,243 we observed no correlation in individual subjects between
serum total IgE and IgG anti-IgE concentrations (Figure 5.7). This may reflect low
subject numbers, interference by IgE-specific autoantibodies with the determination of
total IgE using different techniques244 or a true lack of any relationship.
Although again it might be argued that, as in all similar studies, not all of the properties
of these antibodies or their relative incidence in the entire source populations may have
been characterised in an unbiased manner, it is noteworthy that in no case was their
binding inhibited by prior binding of the IgE to its high-affinity receptor FcRI,
suggesting that these IgG species are able to bind to IgE already attached to its high-
affinity receptor in vivo. This is in contrast to omalizumab, which binds only free IgE.
The findings are congruent with previous studies227 suggesting that the majority of IgG
anti-IgE autoantibodies bind to the C2 or C4 domains of IgE, and not the C3 domain
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to which omalizumab binds245 and which is inaccessible when the IgE is bound to its
high- or low-affinity receptor. The fact that complete removal of total IgG or total IgE
binding proteins abolished basophil modifying activity, whereas the purified IgE binding
proteins retained it, is consistent with the hypothesis that it is entirely attributable to IgG
anti-IgE. Furthermore, that fact that such activity did not “appear” in fractionated serum
from subjects not showing it ex vivo (Figure 5.17) excludes the possibility that it is an
artefact of the separation procedure. Nevertheless, these experiments cannot completely
exclude the possibility that some basophil modifying activity may have reflected the
alternative or additional presence of IgG anti-FcεRI autoantibodies240,246-248. The
unprecedented potential protective effect of some of these antibodies, however, is of great
interest regardless of their precise specificities.
The data in this chapter also provide a precedent that inhibitory IgG anti-IgE
autoantibodies could reduce allergen-induced basophil activation in some patients. The
antibodies that we were able to identify with this effect did not appear to dissociate IgE
from its receptor, a property suggested in previous reports249-251, although some appeared
to be able to prevent allergen binding to surface-bound specific-IgE, presumably without
cross-linking it. This could reflect the inability of IgG anti-IgE in the IgG-IgE-FcεRI 
complex to interact with another IgE molecule on the cell surface for a variety of
reasons252. Further possible mechanisms of basophil inhibition by these antibodies not
explored in the present study are also conceivable, such as cross-linking of FcRIIb with
FcRI253-255. It is worth noting again that the activities of these IgG anti-IgE
autoantibodies are quite different from those of omalizumab, which appears to exert its
clinical effects simply by preventing binding of IgE to its high- and low-affinity
receptors, and has never been described to reduce the intrinsic sensitivity of basophils to
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activation: on the contrary, recent experiments256,257 suggest that sequestration of IgE
during omalizumab therapy renders basophils hypersensitive to activation by cross-
linking of reduced surface-bound IgE molecules, at least partly by resetting of FcRI
coupled intracellular signalling.
Finally, the production of IgG anti-IgE autoantibodies has been well documented in
murine “models” of allergen sensitisation and tolerance258 and in the course of specific
allergen immunotherapy in humans234,259, which induces a vigorous IgG4 response that
could, at least in theory, include IgG anti-IgE autoantibodies. Indeed, one of these studies
on wasp venom immunotherapy234 linked the elevated production of basophil activating
IgG anti-IgE autoantibodies with treatment failure.
In summary, inhibitory IgG anti-IgE autoantibodies may contribute to a natural
regulatory mechanism that could conceivably influence the severity and presence/absence
of diseases with IgE-mediated mechanisms, including asthma and allergic rhinitis, and
the outcomes of therapeutic processes such as allergen immunotherapy and therapy with
exogenous IgG anti-IgE. This demands further research.
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6 Final discussion
6.1 Summary of results
In this project, I have used ImmunoCAP and ImmunoCAP ISAC microarrays for the first
time to detect, quantify and specify IgE in the bronchial mucosa of both atopic and non-
atopic asthmatics. The total IgE concentration in the bronchial mucosal homogenates was
significantly elevated in both the non-atopic and the atopic asthmatics compared with the
controls. Allergen component-specific IgE species were detectable in the sera and biopsy
homogenates of the atopic asthmatics. I failed to detect, however, specific IgE against
any allergen component in both the sera and the bronchial biopsies of the non-atopic
patients, whether asthmatic or not, using the ISAC chip.
IgG autoantibodies binding to both free and FcεRI-bound IgE were detected in patients 
with atopic and non-atopic asthma, as well as controls. While some were able to activate
IgE-sensitised basophils, others inhibited allergen-induced basophil activation, at least
partly by inhibiting binding of IgE to specific allergen. Although the subject numbers
were relatively small and the detection of these antibodies sporadic, these findings are
consistent with the hypothesis that naturally occurring IgG anti-IgE autoantibodies
contribute to both inhibition and activation of basophils in some individuals, and
furthermore in a manner distinct from that of existing therapeutic IgG anti-IgE antibodies
such as omalizumab. The propensity of some individuals to make these antibodies may at
least partly explain the longstanding enigma of why atopic subjects who make allergen-
specific IgE never develop clinical symptoms, and even the observation that omalizumab
therapy is of variable clinical benefit in severe atopic asthma (if its potential inhibitory
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activity on allergen-induced basophil activation is already being subsumed in some
individuals by a naturally occurring autoantibody).
Omalizumab (or placebo) was administered to a group of moderate and severe non-atopic
asthmatics in order to examine its effects on lung function and IgE expression in the
bronchial mucosa. Compared with baseline, the median changes in absolute and %
predicted FEV1 following 20 weeks of therapy (primary outcome measure) were positive
in the omalizumab treated patients despite substantial reduction of existing therapy, but
negative in the placebo treated patients. I also observed a significant reduction in the
median total IgE+ cells (p<0.001) (co-primary outcome measure), in sections of bronchial
mucosal biopsies from the patients treated with omalizumab but not placebo. No
significant changes were observed in median numbers of any of the other cells analysed
following omalizumab or placebo therapy. Very few of the B cells and plasma cells
showed detectable IgE immunoreactivity as expected, so it was impracticable to evaluate
changes. Conglomerates of CD38+ plasmablasts and CD20+ B cells were detected in
approximately 1 in every 10 sections of the mucosa, but again these were insufficient in
number to quantify possible changes.
6.2 Review of hypotheses and final conclusions
The data from analysis of mucosal IgE concentrations shed further light on the presence,
quantity and specificity of IgE in the bronchial mucosa in comparison with a distal site.
The detection of IgE in the bronchial mucosa of non-atopic asthmatics in quantities
equivalent to that of atopic asthmatics supports the hypothesis that IgE synthesis or at
least sequestration is ongoing in this compartment in both atopic and non-atopic
asthmatics. It also further supports the hypothesis that IgE plays a role in the pathogenesis
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or exacerbation of non-atopic asthma. This hypothesis is further supported by additional
preliminary reports that anti-IgE therapy is of benefit in some non-atopic
asthmatics207,208,260-263.
In contrast, the failure to detect allergen-specific IgE utilising the ISAC assay suggests
that this IgE is not directed against the common allergens represented in the ISAC panel.
The most intriguing question here is the possible specificities and functional activities of
the IgE detectable in the bronchial mucosa of the non-atopic asthmatics in quantities
equivalent to those observed in atopic asthmatics. There is ample precedent that IgE
directed against antigens other than allergens may play a role in asthma pathogenesis, for
example RSV IgE in child asthma264 and IgE against enterotoxins of Staphylococcus150
which may themselves induce IgE production by their superantigen activity.
In addition to the possibility that IgE is directed against non-allergen antigens in asthma,
whether or not associated with atopy, it is pertinent to note that IgE pathways may be
activated by non-conventional means in both atopic and non-atopic asthma, including by
IgG autoantibodies directed against IgE or FcεRI223 and IgE with cytokinergic activity134,
while IgE directed against tissue components has been implicated in the pathogenesis of
some diseases associated with atopy such as eczema142.
There has been a small series of studies which has appeared over the past 30 years
suggesting that atopic patients with allergic rhinitis may secrete allergen-specific IgE into
the nasal mucosa in quantities which most likely reflect local, rather than systemic
production88,265. Most recently, Rondon and colleagues have presented evidence90 that a
subset of patients with persistent rhinitis who are non-atopic by conventional criteria
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nevertheless manifest acute symptoms in response to nasal aeroallergen challenge and
elaborate allergen-specific IgE into nasal secretions: they have termed this “local allergic
rhinitis” or “entopy”. The precise origin of this IgE is unknown, but if it reflects local
synthesis one might speculate that relatively prolonged, intense allergen exposure, as
likely occurs in the upper airways, may sometimes result in local IgE synthesis and
further that non-atopic patients may in some circumstances secrete allergen-specific IgE
in response to exposure lower in the respiratory tract.
IgG anti-IgE autoantibodies were detectable in the sera of asthmatics and controls
irrespective of their atopic status, but there was no significant difference in the
concentration of autoantibodies between the groups. This observation was not in
agreement with our original hypothesis that these antibodies are elevated in asthmatics
compared with the controls. However, further characterisation and functional analysis of
these antibodies led to interesting observations. The anti-IgE autoantibodies were
distributed non-uniformly among subjects and induced or inhibited basophil activation. It
is tempting to speculate that autoantibody production could be a distinctive feature of
individual subjects rather than groups, and that the existence of such antibodies may at
least partly address the age old enigma of why many atopic subjects with evidence of IgE
sensitisation to particular allergens do not manifest symptoms on exposure, and why in
some patients, because of the presence of pre-existing, endogenous IgG anti-IgE, the
clinical response to omalizumab is not as extensive as it might have been. Conceivably,
IgE autoantibody status may become part of the definition of new endotypes of asthma in
the future.
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Omalizumab therapy of non-atopic asthmatics reduced bronchial mucosal IgE+ cells and
improved lung function despite withdrawal of conventional therapy, favouring my
hypothesis. However, there were no significant changes in the numbers of individual
inflammatory cells such as eosinophils, plasma cells or B cells between the omalizumab
and placebo treated groups, in contrast to a study of atopic asthmatics (interpretation of
which is complicated by the fact that these milder asthmatics did not improve, as judged
by changes in PC20, following therapy, nor was it clear that the study was powered to
detect such a change)185. Nevertheless, changes in cell numbers do not necessarily equate
with changes in the function of individual cells, especially when these may exist in
clusters and are consequently difficult to enumerate. Furthermore, as expounded in the
introduction to this thesis (Chapter 1), until the interactions between airways smooth
muscle hyperresponsiveness and airways inflammation in regulating airways calibre are
more completely understood, the evidence for involvement of any inflammatory cell in
asthma pathogenesis must remain circumstantial.
Omalizumab may conceivably reduce mast cell and basophil activation caused by IgE
directed against non-allergen antigens or by certain IgG anti-IgE autoantibodies. My data
clearly show that allergen-specific IgE (directed against common allergens) is very
unlikely to be involved in the pathogenesis of non-atopic asthma, raising the question of
how far it is involved in “atopic” asthma: again, does “allergic inflammation” really exist
or is it all alarmin driven? Perhaps the only role of allergen-specific IgE in asthma is to
exacerbate the disease in the short term on allergen exposure of suitably sensitised
individuals.
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Omalizumab may restore innate anti-viral immunity, leading to reduced viral epithelial
damage with consequent alarmin production and increased airways inflammation, which
narrows the calibre of the airways and exacerbates disease. My study has provided
preliminary proof of principle that omalizumab can increase the internal calibre of the
airways in the relatively short term, in presence of reduction of IgE binding to airways
inflammatory cells: cross-linking or binding of IgE to dendritic cells is postulated to
cause impaired interferon responses, as shown in the inner city children study266, in which
omalizumab, administered to asthmatic patients in the few months prior to the September
epidemic, wiped the epidemic out completely.
6.3 Future directions
The work embodied in this thesis suggests several future directions for further research
addressing the role of IgE, and endogenous antibodies directed against IgE in the
pathogenesis of asthma and allergic inflammation.
The data clearly justify closer examination of the possible therapeutic worth of anti-IgE
therapy in non-atopic asthmatics in larger studies with conventional clinical outcomes,
such as the one conducted in inner-city atopic asthmatic children266.
Clearly there must be further scrutiny of the mechanisms whereby IgE may regulate the
severity and stability of asthma, enabling more substantial appreciation of the likelihood
that any given patient will respond clinically to anti-IgE therapy using criteria which
extend far beyond the borderlines of conventional atopic status. ‘Respiratory virus
exacerbated asthma’ might potentially be considered as a new asthma endotype in future;
the role of IgE in determining the consequences of viral exacerbations of disease and the
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role of anti-IgE in the treatment of virally exacerbated asthma would also become an area
of research interest. However, virus exacerbation is such a common phenomenon across
all types of asthma and defining a subgroup based on the criterion of ‘viral exacerbation’
may not be straightforward due to the considerable overlap of various subtypes.
Further consideration should be given to the possible contribution of antigens other than
aeroallergens, and unconventional mechanisms of activation and inhibition of IgE
signalling in the pathogenesis of atopic and non-atopic asthma.
Notwithstanding the findings of this study suggesting that IgE production is not centered
in the bronchial mucosa of asthmatics, it would clearly be of enormous importance to
pinpoint where such production is indeed centralised, if anywhere. This would require
more detailed comparison of bulk IgE production at various mucosal surfaces and in the
reticuloendothelial and lymphatic systems, as well as a deeper understanding of the extent
of IgE trafficking between compartments.
Finally, it would be fascinating to investigate the hypotheses that endogenous IgG, anti-
IgE antibodies may at least partly underlie the lack of clinical responsiveness to allergen
in some atopic patients, limit the clinical responsiveness of some asthmatics to exogenous
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